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Bioprospecting is the systematic search for and discovery of products in nature, with the 
purpose of developing commercial products. The marine environment displays a rich biological 
diversity, as well as a diversity within environmental factors. This environment has necessitated 
the production of potent secondary metabolites by marine organisms in their arms race against 
predators and pathogens, in the battle for space and to increase chances of reproduction.  The 
resulting compounds are generally known to have unique chemical features, often unknown 
from terrestrial sources, as well as interesting biological activities. Due to these factors, they 
are believed to hold an immense potential as lead compounds in development of commercial 
products.  
The aim of this thesis was to isolate and characterise secondary metabolites from extracts of 
eight Arctic, marine invertebrates. Prefractionated extracts were screened for anticancer 
activity, and active fractions were dereplicated to investigate if the bioactive compound(s) was 
novel or had been previously reported. Three compounds believed to be novel were isolated, 
structure elucidated and biologically characterised. A novel compound, named BI-L-665.6 in 
this thesis, was isolated from the organic extract of Bryozoa indet. In addition, Ponasterone A 
(Pon A) and dehydroxy-Pon A were isolated from the organic extract of Alcyonidium 
gelatinosum. Pon A was first isolated from Podocarpus nakaii in 1966, but this is the first time 
that this compound has been isolated from A.gelatinosum. Biological characterisation of the 
isolated compounds detected no anticancer or antibacterial activity at the test concentrations 
employed in the assays. The results from this thesis show that bioprospecting of collected 
marine invertebrates enables discovery of secondary metabolites with novel chemistry, as well 
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The collected marine invertebrates were prepared into two crude extracts: an aqueous and an 
organic extract. Each extract was fractionated into eight fractions. The sample names in this 
thesis are based on an abbreviation of the species name, extract type (W: aqueous extract, L: 
organic extract) and flash fraction number (Table 1). Example: Flash fraction 5 of the organic 
extract of A.gelatinosum is named AG-L-05. In total, 19 fractions were included in the work 
conducted as part of this thesis.  
Isolation of target compounds was conducted on the crude extracts named after their originating 
species and the extraction method. Compounds were isolated from the organic extract of B.indet 
(BI-L) and the organic extract of A.gelatinosum (AG-L). After isolation, the mass-to-charge 
ratio (m/z) of the isolated compounds was added to the extract name. Example: AG-L-449.4 is 
the name for the isolated compound with m/z 449.4 from the organic extract of A.gelatinosum. 
Table 1: Samples were assigned a unique name containing abbreviations indicating species, extraction 
method and flash fraction number. 
Organism Extract Fraction Sample name 
Mycale (Mycale) lingua 
W 5 ML-W-05 
W 6 ML-W-06 
W 7 ML-W-07 
L 4 ML-L-04 
L 5 ML-L-05 
L 6 ML-L-06 
L 7 ML-L-07 
Bryozoa indet  
W 4 BI-W-04 
W 5 BI-W-05 
W 6 BI-W-06 
Porifera indet 
L 6 PI-L-06 
W 6 PI-W-06 
Alcyonidium gelatinosum 
W 4 AG-W-04 
W 5 AG-W-05 
L 5 AG-L-05 
Styela rustica W 5 SR-W-05 
Astarte borealis L 7 AB-L-07 
Nuculana pernula L 5 NP-L-05 
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Humans have always relied on natural resources to survive. This is true both in regard to basic 
needs such as food, shelter and clothes, but also in regard to medicine. The latter point can be 
exemplified by the traditional utilisation of terrestrial plants, either as a whole or parts of it, 
processed or raw, as traditional medicine against various conditions in many cultures. Natural 
resources have formed the basis for traditional medicine that is still being used around the world 
today (Newman, Cragg, & Snader, 2000). Bioprospecting is the systematic search for and 
discovery of natural products (NPs) with the purpose of developing commercial products 
(Ashforth et al., 2010; Mateo, Nader, & Tamayo, 2001). These products can fall into three 
categories: chemicals, genes or designs. The NPs can be utilised as agrochemicals, as lead 
compounds in drug development, in cosmetics, recombinant pharmaceutical proteins, enzymes 
and in mechanical engineering (Mateo et al., 2001).  
1.1.1 Natural products 
NPs refers to compounds produced by a living organism . Some NPs are commonly encountered 
in all organisms and the organism needs to be able to transform and interconvert these NPs in 
order to live, grow and reproduce. These NPs, called primary metabolites, are vitally important 
for the survival of the organism. (Dewick, 2009, p. 7-38). In contrast, there exist compounds 
that are distributed in a much more limited fashion in nature. These compounds are called 
secondary metabolites, but the term NPs is often used when referring to these compounds (and 
not primary metabolites). In this thesis, NPs and secondary metabolites will be used 
interchangeably. These compounds are not necessarily produced under all conditions since they 
are not necessary for the immediate survival, growth, development or reproduction of the 
producing organism. It is believed that the secondary metabolites affect the interaction of the 
organism with its surrounding environment, and that their mode of action can influence long-
term survival (Agostini-Costa, Vieira, Bizzo, Silveira, & Gimenes, 2012). They may enable the 
organism to survive interspecies competition (Engel & Pawlik, 2000; Luter & Duckworth, 
2010), they facilitate reproductive processes (coloring attractants) (Rinehart, 1992) or they can 
provide defensive mechanisms (toxic materials) against pathogens and predators (Cowan, 
1999). Plants, bacteria, fungi and marine invertebrates are well known sources of secondary 
metabolites. In addition to their beneficial effect for the producing organism, the secondary 
metabolites have proven to be useful for a wide range of other applications. This includes  
applications like cosmeceuticals, insecticides, nutraceuticals and pharmaceuticals (Vaishnav & 
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Demain, 2010). In this thesis, the focus will be on finding secondary metabolites that have 
anticancer activities and potential to be developed into commercially available anticancer 
pharmaceuticals.  
The utilisation of NPs within the field of drug discovery has been a remarkable success 
(Newman & Cragg, 2016). An overview of all approved drugs from 1981 to 2014 can be seen 
in Figure 1. The extensive data sets reviewed by Newman and Cragg highlight the key role that 
NPs, and structures derived from or related to NPs, have played in drug discovery in this time 
period. Of the drugs approved between 1981 and 2014, only 27% are synthetic drugs while 67% 
are derived from- or inspired by NPs. This review also highlights the important role NPs have 
played in anticancer drugs approved in this time period (84% of approved anticancer drugs are 
NP derived or inspired) (Newman & Cragg, 2016).  
 
Figure 1: All new approved drugs from 1981 to 2014, n=1562. B: Biological macromolecule, N: Unaltered NP, 
NB: Botanical drug (defined mixture), ND: NP derivative, S: synthetic drug, S*: Synthetic drug (NP 
pharmacophore), /NM: Mimic of NP and V: Vaccine. Figure made with inspiration from reference (Newman & 
Cragg, 2016). 
Despite this, many pharmaceutical companies have ceased their NPs research (David, 
Wolfender, & Dias, 2015; Vederas, 2009). These companies are under a lot of pressure to 
identify a lead compound quickly and profitably. There are certain aspects of NPs that makes 
this challenging, such as a slow identification process, low supply of the compound and their 
complex chemical structure complicating their synthesis. These companies have instead 
preferred screening of synthetic compounds (Vederas, 2009). However, recent advances in 
technology have affected this trend and now there is a re-emergence of NPs in drug discovery 
(Harvey, Edrada-Ebel, & Quinn, 2015). 
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The enormous chemical diversity present in nature suggests that NPs possess several chemical 
properties that make them superior as lead compound compared to synthetic compounds (Feher 
& Schmidt, 2003). NPs have a higher molecular weight (Mw), a higher number of ring systems, 
chiral centers, heavy atoms, hydrogen-bond donors and –acceptors, lower number of rotatable 
bonds and they are less lipophilic and more unsaturated (Clardy & Walshm, 2004; Feher & 
Schmidt, 2003; Muigg, Rosén, Bohlin, & Backlund, 2013). These properties make NPs more 
structurally diverse and more rigid than synthetic compounds (Feher & Schmidt, 2003). The 
NPs have evolved over time to interact with enzymes, receptors and ionic channels in plants or 
animals (David et al., 2015). These compounds have a greater chance of interacting with targets 
in the human body as well, and NPs display a much greater range of bioactivity in a larger 
number of targets than synthetic compounds (Battershill, Jaspars, Long, & Battershill, 2005). 
These characteristics make it clear that it is still important to involve NPs in drug discovery 
despite the time-consuming process it is to identify and develop a lead compound into a 
marketable drug.  
1.1.2 The marine environment 
The ocean covers 70% of earth`s surface and deep-sea environments comprise 90% of the 
global biosphere by volume (Snelgrove, 2016). According to Margulis and Chapman, out of 
the 33 known animal phyla, 32 are found in the ocean and 15 of these are exclusively marine 
(Margulis & Chapman, 2009). The marine environment displays a biological diversity as well 
as a diversity in environmental factors. These diverse conditions have affected the production 
of secondary metabolites, resulting in structurally novel and biologically active secondary 
metabolites that are unknown from terrestrial sources (de Carvalho & Fernandes, 2010). There 
is an abundance of bromine (Br) and chlorine (Cl) ions in seawater. This affects the secondary 
metabolites, and gives a higher likelihood of marine secondary metabolites being halogenated 
(especially brominated), a chemical feature that is uncommon in terrestrial NPs (A. Butler & 
Carter-franklin, 2004; Teeyapant & Proksch, 1993).  
Traditionally, bioprospecting has been focused on terrestrial sources such as plants. This is 
mainly due to the availability of the terrestrial organisms, as well as the tradition for using them 
in medicine. In the 1950s, spongothymidine and spongouridine from the marine sponge Tethya 
crypta (now known as Tectitethya crypta) were discovered (Bergmann & Feeney, 1950, 1951). 
This marked the beginning of the investigation of NPs from the marine environment. In the 
beginning, the compounds were mainly isolated from easily accessible organisms like 
macroalgae. Improvements in scuba and submersible collection technologies made the physical 
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access to greater depths of the ocean possible. In addition, deep-water collections were made 
possible through dredging, trawling and remotely operated vehicles (Cragg & Newman, 2013). 
This resulted in an increase in the number of novel marine NPs reported every year (1340 new 
compounds were reported in 2015 (Blunt, Copp, Keyzers, Munro, & Prinsep, 2017)). The 
majority of marine NPs have been isolated from tropical and temperate waters (Leal, Madeira, 
Brandao, Puga, & Calado, 2012). Research now also focuses on organisms in colder climates, 
such as the Antarctic and Arctic.  This has previously been a more unexplored habitat, but is 
now proving to provide valuable NPs (Blunt, Copp, Keyzers, Munro, & Prinsep, 2014).   
1.1.3 Marine natural products 
As of April 2016, there are seven FDA (U. S. Food and Drug Administration) drug approved 
marine compounds (Figure 2), four compounds in phase III, six compounds in phase II, two 
compounds in phase I/II and 12 compounds in phase I of clinical trials (Mayer, 2016). The first 
approved marine drug was the anticancer compound cytarabine (Cytosar-U®), isolated from 
the sponge Cryptotheca crypta, which was approved in 1969. Since then, six drugs have been 
FDA approved: Vidarabine (Vira-A®, no longer in use) in 1976, ziconotide (Prialt®) and 
omega-3-acid ethyl esters (Lovaza®) in 2004, eribulin mesylate (Halaven®) in 2010, 
brentuximab vedotin (Adcetris®) in 2011 and Trabectedin (Yondelis®) in 2015 (David et al., 
2015; Martins, Vieira, Gaspar, & Santos, 2014; Mayer, 2016).  
 
Figure 2: The chemical structures of the seven approved marine derived drugs as of April 2016 (Vira-A®, no 
longer in use). Adcetris® is covalently attached to a monoclonal antibody (Younes, Yasothan, & Kirkpatrick, 
2012). Lovaza®, Cytosar-U®, Adcertris®, Halaven® and Vira-A® have chemical structures optimised by 
synthesis. They are synthetic- (analogue produced by chemical synthesis) or semisynthetic (using a NP or a natural 
precursor as starting material) derivatives of the secondary metabolites (Gerwick & Moore, 2012). Figure made 
with inspiration from reference (Hanssen, 2014).   
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1.2 Marine invertebrates 
Marine invertebrates do not possess a bony or cartilaginous skeleton (Kozloff, 1990, p. 1). 
Many marine invertebrates are sessile and soft bodied. These organisms are unable to escape 
from predators and are in addition to spikes or physical structures, relying on a chemical defence 
(NPs) to deter predators and pathogens, keep competitors away or to paralyze prey (Leal et al., 
2012).  These NPs have been shown to exhibit bioactivities such as anticancer, antidiabetes and 
antiinflammatory (reviewed by (Senthilkumar & Kim, 2013). In this thesis, marine 
invertebrates from the phyla Porifera, Bryozoa, Chordata, Mollusca and Echinodermata were 
studied (Figure 3). 
 
Figure 3: Eight marine invertebrates were studied in this thesis: S.rustica (A), B.indet (B), A.gelatinosum (C), 
M.lingua (D), S.droebachiensis (E), P.indet (F), A.borealis (G) and N.pernula (H). Photo: Robert Johansen, 
Marbank.   
Many marine invertebrates live in symbiosis with microorganisms. These microorganisms are 
in many cases believed to be the true source of the bioactive secondary metabolites that 
previously were thought to be produced by the invertebrate (Webster & Taylor, 2012). As an 
example, Dolastatin 10 was first isolated from the mollusc Dolabella auricularia (Pettit et al., 
1987), but it was later revealed that the compound was produced by a marine cyanobacterium 
and accumulated by D.auricularia through its diet (Harrigan et al., 1998). Figure 4 shows the 
collected source (A) and the predicted biosynthetic source (B) of marine derived or inspired 
drugs and clinical trial agents (Gerwick & Moore, 2012). These pie charts also illustrate the 
importance of marine invertebrates as the collected source for finding new chemistry with a 
potential for use as commercial products. Many microorganisms are host specific and they have 
been proven difficult to grow in culture (Hansen & Andersen, 2016; Taylor, Radax, Steger, & 
Wagner, 2007). The microorganisms often constitute a large part of the collected sample weight 
(Taylor et al., 2007) and the collected macroorganism biomass can be enough to enable 
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secondary metabolites isolation. Collection of marine invertebrates, as conducted for this thesis, 
is therefore still a feasible approach to obtain bioactive secondary metabolites, as is exemplified 
by the isolation of ianthelline from the Arctic, marine sponge Stryphnus fortis (Hanssen et al., 
2014).  
 
Figure 4: Pie charts illustrating the collected source (A) and the predicted biosynthetic source (B) of marine 
derived or inspired drugs and clinical trial agents. The collected source has often been shown to or is strongly 
suspected of harbouring or feeding upon microorganisms that are the actual producer of the bioactive compound. 
Figure made with inspiration from reference (Gerwick & Moore, 2012). 
1.2.1 Phylum Porifera 
The phylum Porifera consists of multicellular organisms more commonly known as sponges. 
The majority of sponges are marine, sessile organisms. Their bodies are organized around pores 
and chambers where water flows continually due to the beating of a flagella called choanocytes. 
This water current brings in oxygen and food, and takes away carbon dioxide and wastes 
(Kozloff, 1990, p. 73-80). Sponges have microorganisms on their body surfaces and deep inside 
their body. Both the sponge and the microorganisms associated with them can produce a wide 
variety of bioactive molecules (Webster & Taylor, 2012). Previously, the research focused on 
sponges from tropical and temperate waters. More recently, sponges from colder waters of the 
Antarctic and the Arctic have also been investigated (Abbas et al., 2011). In this thesis, Mycale 
(Mycae) lingua and Porifera indet (species not determined) were investigated from the phylum 
Porifera. 
1.2.2 Phylum Bryozoa 
Bryozoa is a phylum of colonial, aquatic animals. The colonies are built up by asexual 
reproduction, where a single individual gives rise to a new colony by budding. The colonies 
can form membrane-like crusts or bush-like colonies on substrates such as kelp, crustaceans, 
stones and rock surfaces (Moen, Svensen, Cochrane, & Pleijel, 2004, p. 393-394). Bryozoans 
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are attached to the substrate and the feeding in bryozoans therefore depends on ciliary activity. 
This ciliary activity creates a current of water that moves food particles toward the mouth. These 
sessile organisms are important fouling organisms on ship bottoms, floating docks and buoys 
(Kozloff, 1990, p. 480-482). Bryozoans have been a source for novel and/or biologically active 
compounds such as the bryostatins (Hornung, Pearson, Beckwith, Longo, & Hornung, 1992). 
In this thesis, A.gelatinosum and B.indet (species not determined) were investigated from the 
phylum Bryozoa.    
1.2.3 Phylum Chordata 
Chordates are bilaterally symmetrical with an internal notochord (a skeletal rod) present at some 
life stage. Organisms in this phylum are very adaptable and can occupy most kinds of habitats. 
This phylum comprises the subphylums Cephalochordata, Urochordata and Vertebrata. All 
chordates are deuterostomes, meaning that the anus forms before the mouth during the embryo 
development stage. A chordate takes in food through the mouth and has a digestive system with 
stomach and intestines (Hickman, 2011, p. 500-501). Bioactive secondary metabolites have 
been investigated in this phylum, antibacterial activity has for example been detected in a 
Defensin compound produced in Branchiostoma japonicum (Teng, Gao, & Zhang, 2012). In 
this thesis, Styela rustica was investigated from the phylum Chordata.  
1.2.4 Phylum Mollusca 
The phylum Mollusca consists of clams, snails, octopuses and their relatives. Even though the 
inner structure and physiology of these organisms are relatively similar, there is a great diversity 
when it comes to exterior body forms in this phylum. The phylum contains organisms ranging 
from small snails to 20 m long squids (Moen et al., 2004, p. 282). Molluscs are found in marine, 
freshwater and terrestrial habitats. The organisms are mostly free-living, and only occasionally 
parasitic. They can be burrowers, bottom feeders or pelagic, and they therefore represent a 
variety of lifestyles (Hickman, 2011, p. 334-336). Some secondary metabolites from molluscs 
have been investigated. From oysters, various bioactive peptides have been discovered with 
antioxidant and anticancer activities (Umayaparvathi et al., 2014). In this thesis, Astarte 
borealis and Nuculana pernula were investigated from the phylum Mollusca.  
1.2.5 Phylum Echinodermata 
This phylum contains sea stars, sea urchins and their relatives. All Echinoderms have a 
calcareous endoskeleton either as plates or as scattered tiny ossicles. Echinoderms have no 
freshwater or terrestrial representatives and the organisms are found at every ocean depth. Apart 
from a few pelagic species, almost all the organisms in this phylum are bottom dwellers 
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(Hickman, 2011, p. 475). The main secondary metabolites produced in this phylum are saponins 
(glycosides). Triterpene glycosides have been isolated from sea cucumbers. Some of these 
glycosides have a cytotoxic activity towards human tumour cell lines (Zou et al., 2003), 
viricidal activity (Maier et al., 2001) or antifungal activity (Murray, Muniaı́n, Seldes, & Maier, 
2001). In this thesis, Strongylocentrotus droebachiensis was investigated from the phylum 
Echinodermata.  
1.3 The Bioprospecting pipeline 
An outline of the workflow in the bioprospecting pipeline conducted at Marbio, and in this 
thesis, is shown in Figure 5. Marbio is an analytical platform for screening, isolation and 
identification of bioactive NPs (Svenson, 2013). The bioprospecting pipeline at Marbio starts 
with bioactivity screening of prefractionated crude extracts (provided by Marbank), and active 
fractions from this initial screening are submitted for dereplication by high resolution-mass 
spectrometry (HR-MS). If the fraction contains a suspected novel compound, or a previously 
reported compound but with a novel bioactivity, the compound will be isolated using 
preparative (prep) high performance liquid chromatography (HPLC)-MS. After the isolation, 
the purity of the compound is examined. If the compound is pure, structure elucidation using 
HR-MS and nuclear magnetic resonance (NMR) spectroscopy is conducted. At the end of this 
pipeline, bioactivity screening is again employed to make a bioactivity profile of the isolated 
compound. The different steps in this isolation approach are discussed in greater detail in the 
subsequent paragraphs.  
 
Figure 5: Overview of the bioprospecting pipeline employed at Marbio and in this thesis. Figure made with 
inspiration from references (Hanssen, 2014; Svenson, 2013).  
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1.3.1 Collection, extraction and prefractionation 
Marbank has the responsibility for collection and preservation of marine organisms for 
scientific research. The material is collected during several annual research cruises in the 
Arctic- and sub-Arctic waters of Norway. The collected organism (invertebrate) is lyophilized 
and extracted to yield an aqueous and an organic (Dichloromethane (DCM): Methanol 
(MeOH)) extract (Svenson, 2013). These crude extracts contain a complex mixture of 
compounds, and prefractionation of the extracts prior to bioactivity screening is advantageous 
because it has been shown to increase the chance of detecting bioactive compounds in bioassays 
(M. S. Butler, 2004).  
The prefractionation can be conducted by using an array of different techniques, but a 
commonly employed technique is liquid chromatography (LC), such as HPLC or flash 
chromatography. At Marbio, a flash chromatographic method resulting in eight fractions with 
known sample weight is used for prefractionation. The advantage with flash chromatography 
is the high loading capacity in addition to the relatively easy process of creating finished 
fractions that can readily be weighed. In this LC technique, the mobile phase is pumped through 
the stationary phase in a tightly closed glass column or in a prepacked cartridge (Bucar, Wube, 
& Schmid, 2013). This results in a prefractionation of the applied sample and the collected 
fractions are analysed using bioassays to detect the presence of bioactive compounds in the 
fractions.  
1.3.2 Bioassay 
A bioassay is an in vitro or in vivo system used to detect the presence of a biologically active 
compound in a sample (Fenner & Gerwick, 2014). Two main bioassay strategies exist: target-
based screening and phenotypic screening. The target-based screening measures the compounds 
ability to affect a defined target. These targets can be enzymes, cellular proteins, receptors, 
DNA or ion channels. This type of screening does not take into consideration the compound`s 
ability to cross the cell membrane or the compound`s stability to cellular enzymes. Therefore, 
an effect in a target-based screening (in vitro) does not necessarily mean that the compound has 
an effect in vivo (Fenner & Gerwick, 2014).  
Phenotypic screening employs whole cell, animal or organ assays. This type of screening 
measures the ability of a compound or a mixture of compounds to produce an effect in the 
cell/organism. This could for example be death of a specific cell type or inhibition of cell 
growth. This type of screening has been successful in discovering new therapeutics and new 
drug classes (Swinney & Anthony, 2011). The screening does not require any prior knowledge 
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about the mode of action of the target compound as it evaluates the compound`s effect on the 
entire system, not on a single target. It also allows the target compound to be screened against 
several drug targets simultaneously. The disadvantage in this type of screening is that the mode 
of action is not determined (Sams-Dodd, 2005).  
In NP drug discovery, a combination of the two types of bioassays are often used. An example 
is the use of phenotypic screening in the initial stage in drug discovery, and then the use of 
target-based screening as follow-up screens to possibly shed light on the mode of action for the 
isolated compound. This enables a greater detection rate in the beginning of the bioprospecting 
pipeline because the extract (or prefractionated extract) is screened against several drug targets 
simultaneously (Swinney & Anthony, 2011). In addition, NPs can have activities with new 
modes of actions against unvalidated targets or targets for which no target-based assays exist, 
and then will not be discovered through target-based screenings. Fractions that give a positive 
result in the initial bioassay screening are submitted for dereplication using LC-MS.  
1.3.3 Dereplication 
Dereplication is a crucial step in NP drug discovery. This step is conducted prior to isolation 
and aims to identify known compounds in bioactive extracts or fractions to avoid replication of 
previously conducted work. When dereplication is conducted as part of the bioprospecting 
pipeline, the probability of rediscovery and reisolation of a previously well characterised 
compound is lower. Ideally, known compounds whose bioactivity have been examined 
previously are removed from consideration before the isolation process begins, and limited 
resources are therefore used more efficiently (Blunt & Munro, 2014).  
A widely-used approach to dereplication is using LC-HR-MS, followed by database searches. 
HR-MS gives the Mw and isotopic patterns of compounds (see section 1.3.5.1 “Mass 
spectrometry”). The isotopic patterns and the exact mass can be used to calculate the elemental 
composition for compounds in the sample. Finally, the elemental composition, bioactivity 
profile and taxonomic information of the compound can be used to search against external or 
internal databases for potential matches with known compounds (Lindequist, 2016). Examples 
of databases that can be used for this type of search is MARINLIT, Dictionary of Natural 
Products, Chemspider and SciFinder. Even though dereplication lowers the probability of 
rediscovery and reisolation, this process is merely a calculation based on the elemental data that 
are available. This means that the calculated elemental composition can be incorrect and 
therefore, there is a chance of rediscovery and reisolation. However, the probability of this is 




Compounds need to be isolated to allow for structure elucidation as well as bioactivity screening 
of the isolated compounds. Several chromatographic techniques are available for further 
fractionation and purification of NPs (Sasidharan, Chen, Saravanan, Sundram, & Latha, 2011), 
and prep HPLC is commonly used for NP isolation. This technique is versatile and robust, and 
it provides the researcher with a high resolving power that is necessary for purifying NPs 
mixtures (Seger, Sturm, & Stuppner, 2013). The results from dereplication are used to decide 
which compound(s) to isolate. In addition, the sample is investigated for the presence of other 
compounds that can be included in the isolation. Even though these compounds might not have 
displayed bioactivity in the initial bioactivity screening, there is a chance that these compounds 
will display other bioactivities than what the sample was initially screened against. The 
researcher is in this sense an opportunist and will include compounds that are easily isolated 
from other impurities and seems to be present in the sample in a fairly large amount.  
1.3.4.1 Prep HPLC-MS 
At Marbio, prep HPLC-MS is used for purification of target compounds (Figure 6). In this 
system, the sample is injected onto the HPLC column and compounds are separated based on 
their affinity for the column packing material and the mobile phase (Neue, 1997, p. 115). After 
separation in the column, a flow splitter splits the mobile phase to the fraction collector and the 
ultraviolet (UV) detector and MS detector. Only a small part of the sample (about 1%) is 
analysed in the UV detector and MS. The majority of the sample (about 99%) is collected in 
fractions. The fractions from several individual injections of the sample can be pooled and 
dried, and used in another round of HPLC separation, if the previous HPLC separation round 
was not sufficient to get a pure compound. A computer controls the entire system, and receives 




Figure 6: Schematic overview of the prep HPLC-MS (prep HPLC-UV-ESI-single quadrupole MS system) used 
for compound isolation in this thesis. Figure made with inspiration from reference (Hanssen, 2014).  
Reverse phase (RP) prep HPLC is a popular method used in NPs isolation. In RP prep HPLC, 
a non-polar stationary phase and a polar mobile phase are employed to isolate NPs (Neue, 1997, 
p. 4). The columns are usually silica-based with additional groups coupled to the silica. It is the 
surface modifications of this packing material that determines the interactions that occur 
between the target compound(s) and the stationary phase inside the column. The solvents used 
to elute the compounds in RP prep HPLC is often a mixture of water and organic solvents such 
as acetonitrile (ACN) or MeOH.  The water is used as the weak solvent and the strong organic 
solvent (for example ACN) is used to elute the target compound(s) from the column (Bucar et 
al., 2013; Latif & Sarker, 2012). 
During the isolation process, several different HPLC columns and different elution gradients 
are generally necessary to isolate the target compound(s). One essential part of the isolation 
process is to establish the isolation strategy that will be used for separating the target 
compound(s) from the rest of the sample matrix. The strategy is often established by conducting 
scouting runs on a small amount of the sample with different columns to determine which 
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columns gives the best separation of the target compound(s) from other sample constituents. 
These scouting runs are the basis for the isolation strategy and determines which columns to 
use in the different rounds of HPLC separation in order to eliminate impurities from the target 
compound(s) (Latif & Sarker, 2012). The researcher can in general use a gradient of mobile 
phases or isocratic mobile phase conditions to isolate the target compound(s). In isocratic 
conditions, the solvent mixture is kept constant throughout the isolation. If the target 
compound(s) elutes over a broader concentration range of the mobile phase however, the 
isocratic conditions will not be suitable for isolation. In this case, the researcher often uses a 
truncated version of the initial gradient used during column investigation (scouting run). The 
starting conditions will be the solvent system used in the scouting run and the end conditions 
will be the concentration of mobile phase required to elute the last desired peak from the 
column. When the solvent system is decided, the injection volume can be increased until the 
loading and separation limits have been reached (Neue, 1997, p. 310-315).   
The desired compounds will be collected in fractions. The fraction collector of the prep HPLC-
MS can be programmed to collect by time or by mass triggering. Collection by mass triggering 
uses the MS data to trigger the collection of compounds eluting from the HPLC column. This 
method combines the chromatographic separation of the HPLC column with real time MS data, 
making it a powerful tool in NP isolation. When the system is set to collect by elution time, the 
same time interval is collected for all the sample injections. While collection by time triggered 
fractionation can be affected by drifts in the retention time between different injections, mass 
triggering fractionation will not be affected by this as this method is set to collect predefined 
masses (Latif & Sarker, 2012).  
1.3.5 Structure elucidation 
Several different techniques exist for use in structure elucidation, such as NMR, HR-MS, UV–
visible spectroscopy, infrared absorption spectroscopy and atomic force microscopy (AFM) 
(Hanssen, Schuler, et al., 2012; Seger et al., 2013). Due to the chemical complexity of NPs, a 
combination of different techniques is often necessary to elucidate the structure of the isolated 
compound(s) (Hoffman, 2004, p. 332-394).  
1.3.5.1 Mass spectrometry 
MS determines the mass of a molecule and this is achieved by measuring the molecule`s m/z 
ratio. A MS consists of four components: a sample inlet, an ionization source, a mass analyser 
and an ion detector (Figure 7). The sample inlet introduces sample molecules to the instrument 
where they are converted to ions in the ionization source. Different ionization sources exist, 
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such as electrospray ionization (ESI), electron ionization (EI) and matrix-assisted laser 
desorption/ionization (MALDI). ESI is the ionization source used in the HR-MS systems found 
at Marbio. This ionization source creates a fine spray of highly charged droplets (dispersed into 
a fine spray from a metal nozzle) in the presence of an electrical field. Dry gas and heat are 
applied to the droplets to evaporate the solvent. ESI involves a continuous introduction of 
solution and it is suitable as an interface with for example HPLC. After the ions are produced, 
they are electrostatically pushed into the mass analyser where they are separated according to 
their m/z. Finally, the detector converts the ion energy into electrical signals that are transmitted 
to a computer and a mass spectrum is produced (Bouslimani, Sanchez, Garg, & Dorrestein, 
2014; Siuzdak, 2003, p. 5-15). The mass spectrum is a plot of the relative abundance of the ions 
as a function of the m/z ratio. This spectrum gives information about the mass, as well as the 
isotopic pattern of the compound, and can be used to calculate the elemental composition of 
compounds (Kind & Fiehn, 2010).   
 
Figure 7: Overview of the four components of a MS system: sample inlet, ionization source, a mass analyser 
and an ion detector. Figure made with inspiration from reference (Silverstein, Webster, & Kiemle, 2005, p. 419). 
1.3.5.2 Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy measures the physical and chemical properties of molecules and this is 
achieved by exploiting the magnetic properties of certain atomic nuclei. The technique relies 
on NMR, a physical phenomenon where nuclei in a magnetic field absorb and re-emit 
electromagnetic radiation.  1H and 13C are the two most commonly examined nuclei. In general, 
the principle of NMR involves two sequential steps. First, randomly oriented nuclei are 
subjected to an external magnetic field which they will align either with or against (Figure 8). 
Alignment against the magnetic field requires the least amount of energy. Second, an 
electromagnetic pulse (usually radio frequency) causes the nuclei to flip, from aligning with 
(lower-energy spin state) to aligning against (higher-energy spin state) the magnetic field. When 
the radiation is switched off, the nucleus re-emits the absorbed energy and relaxes back to the 
lower energy state. This emitted energy signal produces a measurable signal called the 
resonance frequency, and the resonance frequency is affected by the molecule`s atomic 
properties. The resonance frequency is processed into a NMR spectrum (Mlynárik, 2016; Pauli, 
Jaki, & Lankin, 2005; Silverstein et al., 2005, p. 106). NMR spectrum can be either one-
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dimensional (1D) or two-dimensional (2D). 1D experiments are analysis of a single nucleus, 
such as 1H NMR and 13C NMR. 2D NMR provides more information about a molecule than 1D 
NMR because it involves data plotted in a space defined by two frequency axes rather than just 
one (Silverstein et al., 2005, p. 245-251). To elucidate the structure of a complex compound, a 
combination of several NMR experiments, as well as other analytical data, are often required. 
After the structure is elucidated, the bioactivity profile of the isolated compound can be 
established.  
 




 is of lower energy since it is aligned with the field, while the spin state - 
1
2
 is of higher energy since it is opposed 
to the applied field (Silverstein et al., 2005, p. 106).  
1.3.6 Bioactivity profiling of isolated compounds 
After structure elucidation, the bioactivity profile of the isolated compound is determined. This 
includes confirming or disproving the initial bioactivity that was detected in the active fraction 
prior to isolation. In addition, the compound can be submitted to general bioactivity profiling 
including bioassays different from the one where the initial bioactivity was detected. It is 
favourable to combine the use of phenotypic screening and target-based screening in the 
bioactivity profiling (Swinney & Anthony, 2011). The compound can for example be screened 
against a wide range of targets for different disease areas or it can be screened in target-based 
screenings with the aim of determining the mode of action for one specific disease area.  
When the bioactivity profile of the isolated compound has been investigated, the isolated 
compound`s efficiency is determined. This can be achieved by determining the concentration 
ranges for minimum inhibitory concentration (MIC) or the lowest concentration resulting in 
50% inhibition (IC50).  
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1.3.7 Commercialization of natural products 
Before a NP with an elucidated structure and confirmed in vitro bioactivity can be made 
commercially available as a drug, many challenges need to be addressed. Drug development 
comprises all activities that are necessary for transforming a NP into a product that is approved 
for marketing (Rang, 2006, p. 221). A technical development of the compound is conducted as 
part of a lead optimisation. The safety and efficiency of the compound are investigated in pre-
clinical and clinical trials, before the compound is marketed as a drug. The road from discovery 
of the NP to a marketable drug is a complex and time-consuming process (Rang, 2006, p. 257-




2 Aim of the thesis 
The overall aim of this thesis was to identify and isolate bioactive secondary metabolites from 
Arctic, marine invertebrates. The main target activity was anticancer, and results from a primary 
anticancer screening conducted at Marbio were used as a starting point for this thesis.  
The key objectives of the thesis were to:  
1. Confirm anticancer activity detected in an initial bioactivity screening, in a secondary 
anticancer screening  
2. Dereplicate the bioactive fractions to identify target compounds 
3. Establish an isolation strategy to enable isolation of the target compounds in sufficient 





3 Materials and methods 
An overview of the various experimental steps in this thesis can be seen in the flow chart on 
page IV. 
3.1 Biological material 
Arctic, marine invertebrates were collected as described in Table 2, at various locations. The 
biomass samples were stored at -22˚C in the dark before being extracted and prefractionated as 
described in section 3.2.1 “Extraction” and in section 3.2.2 “Prefractionation of crude extracts 
(flash chromatography)”.  
Table 2: Overview of the Arctic, marine invertebrates investigated in this thesis. The species were collected at 






















































57 Agassiz trawl 
Porifera indet 03.04.2007 71.1498N, 
18.6555E 
Tromsøflaket, Troms 190 Beam trawl 
 
Each sample was assigned a unique name containing abbreviations indicating samples 
originating species, extraction method and flash fraction. For example, BI-W-04 is the fourth 
flash fraction of the water extract of B.indet. A complete list of sample names can be seen in 
Table 3. These abbreviations are used throughout the text in this thesis and can also be found 




Table 3: Each sample was assigned an abbreviation indicating samples originating species, extraction method 
and flash fraction. In total, 19 samples from eight Arctic, marine invertebrates were chosen for further analysis 
in this thesis.  
Organism Extract Fraction Sample name 
Bryozoa indet W 4 BI-W-04 
W 5 BI-W-05 
W 6 BI-W-06 
Styela rustica W 5 SR-W-05 
Mycale (Mycale) lingua L 4 ML-L-04 
L 5 ML-L-05 
L 6 ML-L-06 
L 7 ML-L-07 
W 5 ML-W-05 
W 6 ML-W-06 
W 7 ML-W-07 
Alcyonidium gelatinosum L 5 AG-L-05 
W 4 AG-W-04 
W 5 AG-W-05 
Astarte borealis L 7 AB-L-07 
Nuculana pernula L 5 NP-L-05 
Strongylocentrotus 
droebachiensis 
L 1 SD-L-01 
Porifera indet L 6 PI-L-06 
W 6 PI-W-06 
 
3.2 Sample handling routinely conducted at Marbio 
Marbank routinely produces crude extracts from collected organisms. These crude extracts are 
prefractionated as part of the routine work at Marbio. Based on results from the primary 
anticancer screening of such fractions, 19 fractions were chosen for further analysis in this 
master thesis. The procedure described in section 3.2 “Sample handling routinely conducted at 
Marbio” to section 3.3 “Sample selection based on primary anticancer screening” was 
conducted at Marbank and Marbio as part of their routine work prior to the start of this master 
thesis. The procedure described in section 3.4 “Bioassays” and onwards was conducted as part 





The material and equipment used during extraction can be seen in Table 4. 
Table 4: Materials and equipment used during extraction of the marine invertebrates. 
Materials/Equipment Supplier 
Rotary evaporator, Heidolph Laborota  Heidolph Instruments GmbH & Co, Germany 
Whatman® qualitative filter paper, grade 3, 1003-090 Sigma-Aldrich, MO, USA 
Ultra-pure water Merck KGaA, Germany 
Dichloromethane, 34856 Sigma-Aldrich, MO, USA 
Methanol, 34860-M Sigma-Aldrich, MO, USA 
 
The freeze-dried organisms were ground and extracted twice with ultra-pure water (24 hours  
and 30 minutes (min)) at 5˚C in the dark. After centrifugation (two rounds) the supernatant was 
removed, combined and dried. The resulting powder was termed the aqueous extract. The 
remaining pellet was extracted twice with a 1:1 (vol:vol) mixture of DCM and MeOH (24 hours 
and 30 min) at 5˚C in the dark. The mixture was vacuum-filtrated through a Whatman Ø 125 
mm no. 3 filter. The resulting filtrate was reduced to a concentrated liquid under vacuum. This 
concentration resulted in a finished organic extract. Both the aqueous and the organic extracts 
were stored at -23˚C until use.  
3.2.2 Prefractionation of crude extracts (flash chromatography) 
The material and equipment used during prefractionation of crude extracts with flash 
chromatography can be seen in Table 5. 
Table 5: Materials and equipment used during prefractionation of organic and aqueous extracts of marine 
invertebrates.  
Materials/Equipment Supplier 
Biotage® HPFC SP4 Flash Purification System  Biotage, Sweden 
Biotage®SNAP Cartridge KP-Sil 10 g, FSK0-1107-0010 Biotage, Sweden 
Universal Shaker SM 30 Edmund Bühler GmbH, Germany 
Rotary evaporator, Heidolph Laborota  Heidolph Instruments GmbH & Co, Germany 
Syncore® Polyvap Büchi, Switzerland 
Heto PowerDry® PL9000 Freeze Dryer Thermo Fisher Scientific, MA, USA 
Diaion®HP-20SS, 13615-U Sigma-Aldrich, MO, USA 
Methanol, 34860-M Sigma-Aldrich, MO, USA 
Acetone, 34850 Sigma-Aldrich, MO, USA 
Dimethyl sulfoxide, D4540 Sigma-Aldrich, MO, USA 




Approximately 1 g of extract was transferred to a round bottom flask and dissolved in 10 mL 
hexane. To this mixture, 2 g Diaion® HP-20SS was added before the mixture was dried under 
vacuum. The dried sample was added to the top of a flash column packed with 6 g Diaion® 
HP-20SS equilibrated with 5:95 (vol:vol) MeOH: ultra-pure water. Fractionation was 
performed using Biotage HPFC SP4 flash purification system and a gradient of mobile phases 
(water, MeOH and acetone) (Table 6-left). The gradient was pumped with a flow of 12 mL/min, 
and every fraction was collected for 2 min. The fractions were combined as described in Table 
6 (right), and dried under vacuum. This resulted in eight dried fractions (called flash fractions 
from this point on) and these flash fractions were dissolved in dimethyl sulfoxide (DMSO) in a 
concentration of 40 mg/mL. The fractions were stored in CRYO tubes at -23˚C in the dark until 
further use (see section 3.3 “Sample selection based on primary anticancer screening”).  
Table 6: Left) Mobile phase gradient used during flash chromatography prefractionation. Right) After 
prefractionation with flash chromatography, the fractions were pooled as described in this table and dried under 
vacuum. The resulting eight flash fractions were screened in the initial anticancer screening at Marbio.     
 
3.3 Sample selection based on primary anticancer screening 
The samples selected to be worked with in this thesis had all shown activity against a human 
melanoma cancer cell line (A2058) in the ongoing primary anticancer screening (test 
concentration 50 µg/mL) conducted at Marbio. The results from all samples screened in this 
assay in the fall of 2015 were examined and all samples resulting in less than 50 % remaining 
cell survival were nominated for secondary anticancer screening. From these preliminary 
results, 19 flash fractions (from eight different Arctic, marine invertebrates) with anticancer 
activity were chosen for further examination in this thesis. This marks the end of the procedure 
conducted at Marbio prior to the start of this master thesis. The 19 fractions (Table 3) were 
investigated as described in section 3.4 “Bioassays” and onwards for this master thesis.  
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3.4 Bioassays  
3.4.1 Anticancer screening 
The material and equipment used in the anticancer screening are listed in Table 7.  
Table 7: Materials and equipment used in anticancer screening. 
Materials/Equipment Supplier 
DTX 880 multimode detector  Beckman Coulter, CA, USA 
CO2 Incubator, model: MCO-18AIC Panasonic Biomedical, Japan 
Herasafe biological safety cabinet (Class II) Thermo Fisher Scientific, MA, USA 
Dulbecco`s Modified Eagle Medium (D-MEM), high glucose, 
GlutaMAX™ Supplement, HEPES, 32430027 
Thermo Fisher Scientific, MA, USA 
Earle`s minimal essential medium (E-MEM) with 20 mM HEPES, 
F4315 
Merck KGaA, Germany 
Roswell park memorial institute medium (RPMI-1640), FG 1383 Merck KGaA, Germany 
Fetal Bovine Serum (FBS), S 0115 Merck KGaA, Germany 
Gentamycin [10 mg/mL], A2712 Merck KGaA, Germany 
L-Alanyl-L-glutamine [200 mM], K 0302 Merck KGaA, Germany 
NEA - Non essential amino acids (100x), K 0293 Merck KGaA, Germany 
Sodium pyruvat 100 mM, L 0473 Merck KGaA, Germany 
Sodium bicarbonate 7,5%, L 1713 Merck KGaA, Germany 
Cell Titer 96® Aqueous One Solution Reagent, G358B Promega, WI, USA 
DMSO, D4540 Sigma-Aldrich, MO, USA 
Triton™ X-100, T8787 Sigma-Aldrich, MO, USA 
Trypsin (1:250), 27250018 Thermo Fisher Scientific, MA, USA 
A2058 (ATCC® CRL-11147™) LGC Standards, UK 
MRC-5 (ATCC® CCL-171™) LGC Standards, UK 
MCF-7 (ATCC® HTB-22™) LGC Standards, UK 
HT-29 (ATCC® HTB-38™) LGC Standards, UK 
 
Four adherent cell lines were used in the anticancer screening and these cell lines were sustained 
in culture (for appropriate growth medium, see Table 8). The adherent cells were split 
(trypsinated) twice a week. After trypsination, the cells were resuspended in appropriate growth 
medium. A new culture flask was prepared with fresh media, and transferring sufficient 
amounts of resuspended cells to reach a cell density of 70 – 80% before the next round of cell 
splitting. The rest of the cell suspension (not used for further growth of the cell lines) was 
available for use in anticancer screening (see sections 3.4.2 “Secondary anticancer screening”, 
3.4.3 “Tertiary anticancer screening” and 3.4.4 “Bioactivity profiling of isolated compounds”). 
Microtiter plates (96 wells) were prepared by seeding cells at 2000 cells/well (A2058, MCF-7 
and HT-29) or 4000 cells/well (MRC-5). 
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Table 8: Cell lines and appropriate growth medium used in the anticancer screening. 
Cell line Cell type Growth medium 
A2058 Human 
melanoma 
DMEM with 10 % FBS, 1% L-Alanyl-L-glutamine and 0,1 % 
gentamycin 
MRC-5 Human lung 
fibroblast 
E-MEM with 10% FBS, 0,1 % gentamycin, 1 % NEA, 1% 
sodium pyruvate, 1% sodium bicarbonate and 1% L-Alanyl-L-
glutamine 
MCF-7 Human breast 
carcinoma 
E-MEM with 10% FBS, 0,1 % gentamycin, 1 % NEA, 1% 
sodium pyruvate, 1% sodium bicarbonate and 1% L-Alanyl-L-
glutamine 
HT-29 Human colon 
carcinoma 
RPMI with 10 % FBS, 1% L-Alanyl-L-glutamine and 0,1 % 
gentamycin 
 
3.4.2 Secondary anticancer screening 
The prefractionated samples (see section 3.2.2 “Prefractionation of crude extracts (flash 
chromatography)”) were screened against the malignant cell line A2058. The samples were also 
screened against the non-malignant lung fibroblast MRC-5 to investigate the sample`s toxicity 
against normal human cells. After seeding of 96-well microtiter plates as described above, the 
plates were incubated overnight in 37˚C, 5% CO2, to allow settling of the cells. The following 
day, the growth medium was removed from the microtiter plate wells and new growth medium 
with samples (preheated to 37˚C) was added to the wells. The cell lines were exposed to 
different concentrations of the samples: 50, 25 and 10 μg/mL. The total assay volume was 100 
μL and each sample was screened in duplicates. Wells with 100 μL growth medium were used 
as negative control. Cells treated with 0.5% triton were used as a positive control. The cells 
were exposed to the samples for 72 hours (37˚C, 5% CO2).  
Cell viability was determined by a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, 2012). 
After 72 hours, 10 μL Aqueous One was added to each well in the microtiter plate. The plates 
were incubated for one hour in 37˚C, 5% CO2. The cell survival was then analysed by measuring 
light absorbance using a DTX 880 multimode detector at 485 nm. Using a mean for the positive 
and negative control, the percentage of cell survival was calculated using formula 1 
Formula 1: 
Average measurement test sample-mean positive control
Mean negative control- mean positive control
*100=% Cell survival     
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Samples, whose activity was confirmed through the secondary anticancer screening, were 
nominated for further investigation using ultra performance liquid chromatography (UPLC)-
HR-MS analysis (see section 3.5 “Dereplication of active samples”).  
3.4.3 Tertiary anticancer screening 
Collected fractions from the refractionation of AG L-05 (see section 3.6 “Refractionation of 
AG-L-05 with prep HPLC-MS”) were analyzed in a tertiary anticancer screening. The freeze-
dried fractions in deep well plates were dissolved by adding 7,5 μL DMSO to each well. The 
plates were incubated in room temperature with constant shaking for 30 min. After this 
incubation, 750 μL of E-MEM was added to each well and the plate was incubated at room 
temperature with shaking for 30 min. Finally, 750 μL E-MEM was added to each well and the 
samples were incubated at room temperature with constant shaking for 10-15 min.  
The tertiary anticancer screening was performed as described in the secondary anticancer 
screening (section 3.4.2 “Secondary anticancer screening”), apart from the sample volume. In 
sample wells, 50μL E-MEM and 50 μL of the dissolved fractions were added to the cell lines.  
3.4.4 Bioactivity profiling of isolated compounds  
3.4.4.1 Anticancer screening 
An anticancer screening of the isolated compounds (see section 3.7 “Isolation of target 
compounds from extract BI-L and AG-L using prep HPLC-MS”) was performed on the cell 
lines A2058, MRC-5, MCF-7 and HT-29. The cell lines were exposed to different 
concentrations of the isolated compounds (see Table 9). In addition, DMSO controls were 
conducted with the same percentage of DMSO as what was present in the sample wells with 
AG-L-465.3 and AG-L-449.4, because it exceeded the recommended DMSO concentration of 
1% (Eastwood et al., 2007). The screening was conducted as described in section 3.4.2 




Table 9: The isolated compounds AG-L-465.3, AG-L-449.4 and BI-L-665.6 were tested in an anticancer 
screening. Left) The cell lines A2058, MRC-5, MCF-7 and HT-29 were exposed to different concentrations of the 
samples AG-L-465.3 and AG-L-449.4. In addition, DMSO controls were screened for the percentage of DMSO 
that was present in the sample. Right) The cell lines A2058, MRC-5, MCF-7 and HT-29 were exposed to 
different concentrations of the sample BI-L-665.6. 
 
3.4.4.2 Antibacterial screening 
Materials and equipment used in the antibacterial screening can be seen in Table 10. 
Table 10: Materials and equipment used in the antibacterial screening. 
Material/Equipment  Supplier 
Heated Incubator MIR-262 Panasonic Healthcare, Japan 
Incubator Unimax 1010  Heidolph Instruments GmbH & Co, Germany 
Victor Multilabel Counter  Perkin Elmer, MA, USA 
Software: WorkOut 2.5 Dazdag, UK 
Herasafe biological safety cabinet (Class II) Thermo Fisher Scientific, MA, USA) 
Mueller Hinton broth (MH), 275730 Becton Dickinson and Company, NJ, USA 
Brain heart infusion broth (BHI), 53286 Sigma-Aldrich, MO, USA 
Sodium chloride, S5886 Sigma-Aldrich, MO, USA 
Ultra-pure water Merck KGaA, Germany 
Blood agar plates University hospital of North Norway(UNN), Norway 
Luria-Bertoni (LB) plates University hospital of North Norway (UNN), Norway 
Glycerol, G5516 Sigma-Aldrich, MO, USA 
Gentamycin (10mg/mL), A 2712 Merck KGaA, Germany 
Staphylococcus aureus, ATCC® 25923 LGC Standards, UK 
Escherichia coli, ATCC® 25922 LGC Standards, UK 
Enterococcus faecalis, ATCC® 29212 LGC Standards, UK 
Pseudomonas aeruginosa, ATCC® 27853 LGC Standards, UK 
Streptococcus agalactiae, ATCC® 12386 LGC Standards, UK 
Preparation of bacterial strains 
The antibacterial activity of the isolated compounds BI-L-665.6, AG-L-05-465.3 (Pon A) and 
AG-L-05-449.4 (dehydroxy-Pon A) (see section 3.7.2 “Isolation of target compounds from 
extract BI-L (prep HPLC-MS)” and section 3.7.3 “Isolation of compounds from extract AG-L 
(prep HPLC-MS)”) were screened against five bacterial strains (Table 11). These bacterial 
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strains were stored in the same growth medium as they were cultivated in, with 10% glycerol 
at -80˚C. When in use, the bacteria were kept on blood agar plates (maximum 1 month), with 
re-streaks every second week for maintenance of the bacteria. When the antibacterial screening 
was performed, the five different bacterial strains were seeded from blood agar plates to 8 mL 
growth media (See Table 11 for appropriate growth medium). These bacterial suspensions were 
incubated over night at 37˚C.  
Table 11: Test bacteria utilised in the antibacterial screening, as well as their appropriate growth medium and 
cultivation time (second day).  
Bacteria Growth medium Incubation second day (hour)  
S. aureus MH broth 2.5  
E. coli MH broth 1.5  
E.faecalis BHI broth 1.5  
P.aeruginosa MH broth 2.5  
S. agalactiae BHI broth 1.5  
 
The following day, 2 mL of the overnight bacterial cultures were transferred to 25 mL fresh 
medium for incubation with shaking for 1.5/2 hours (see Table 11 for appropriate incubation 
time) until the growth reached 0.5 McFarland standard (1.0x108 bacteria/mL). After incubation, 
the bacterial suspensions were diluted 1:1000 in fresh media before being used in the 
antibacterial assay.  
Preparation of 96-well microtiter plates for antibacterial screening 
The compounds BI-L-665.6, AG-L-05-465.3 (Pon A) and AG-L-05-449.4 (dehydroxy-Pon A) 
were screened in final test concentration of 10, 5, 2.5, 1.25, 0.625 and 0.3125 µM, in duplicates, 
in the antibacterial assay. The compounds were dissolved in DMSO and diluted in sterile ultra-
pure water to concentrations 20, 10, 5, 2.5, 1,25 and 0,625 µM. 50µL of the samples were added 
to 5 different microtiter plates (one for each bacterial strains) in two parallels. 50µL of the 
diluted bacterial suspension were added to the samples (diluting the sample 1:2, giving the 
previously mentioned test concentration).  
For a negative control, 50 µL growth media and 50µL sterile ultra-pure water were used. For 
positive control, 50µL sterile ultra-pure water and 50µL of the diluted bacterial suspension 
were used. The microtiter plates were incubated for 22 hours at 37˚C. After this incubation, 




Low absorbance indicated bacterial growth inhibition, and Abs600 values were used to define 
the compounds as active, inactive or questionable: 
    A < 0.05 
    Q = 0.05-0.09 
    I > 0.09 
Gentamycin control and control of colony forming unit (CFU) 
A gentamycin control and control of colony forming unit (CFU) were conducted to ensure that 
the bacterial strains were growing properly and that the assay was working. This is conducted 
routinely at Marbio. The gentamycin control was conducted with final test concentrations 
varying from 0.01 µg/mL to 16 µg/mL, to find the MIC values for gentamycin. 50 µL of the 
gentamycin controls was added to 50 µL bacterial solution. The plate was incubated over-night 
at 37˚C. If the MIC-values for gentamycin was within one titer step outside of the reference 
MIC-values (see Table 12), it was decided that the assay was working. The MIC-values were 
evaluated visually, and Table 12 shows the reference MIC-values for each bacterium. 
Control of CFU was conducted by using the bacterial solutions after incubation (1.5/2.5 hour) 
on the second day of the antibacterial screening. This bacterial solution was diluted in 0.9% 
NaCl solution: First 1:100, then 1:100 again and 1:10 times two. 100 µL of the two last dilutions 
(1:100 000 and 1:1 000 000) were plated in two parallels on LB plates, and incubated over-
night at 37˚C. The next day, the number of colonies was counted and CFUs were calculated and 
controlled against the standard CFU ranges listed in Table 12. If the calculated CFU were within 
the range of the standard CFU ranges, the bacterial growth was deemed normal.   
Table 12: Reference MIC-values and CFU ranges for the test bacteria utilised in antibacterial screening. 
Test bacteria Reference MIC-values for 
gentamycin (µg/mL) 
CFU ranges 
S.aureus 0.25 0.5-3x105 CFU/mL 
E.coli 0.5 0.5-3x105 CFU/mL 
E.faecalis 10 0.5-3x105 CFU/mL 
P.aeruginosa 0.5 3-7x104 CFU/mL 





3.5 Dereplication of active samples 
The material and equipment used in UPLC-HR-MS analysis of active samples from the 
secondary anticancer screening are listed in Table 13.  
Table 13: Material and equipment used in dereplication of active samples from the secondary anticancer 
screening employing UPLC-HR-MS analysis. 
Material/Equipment Supplier 
Acquity UPLC ® BEH, 2.1x100 mm, 1.7 μm column Waters, MA, USA 
Aquity Sample Manager Waters, MA, USA 
Aquity Binary Solvent Manager Waters, MA, USA 
2998 Photodiodide Array Detector Waters, MA, USA 
LCT Premier  Waters, MA, USA 
LiChrosol® Acetonitrile (hypergrade for LC-MS), 1.00029 Merck KGaA, Germany 
Formic Acid ULC/MS 99%, 069141 Biosolve B.V., Netherland 
Methanol LC-MS Ultra CHROMASOLV®, 14262 Thermo Fisher Scientific, MA, USA 
Ultra-pure water Merck KGaA, Germany 
 
The active samples from the secondary anticancer screening (see section 3.4.2 “Secondary 
anticancer screening”), as well as the fraction eluting directly before and directly after the active 
fraction(s), were removed from the freezer and thawed in room temperature. In a deep well 
plate, 5 μL of the fraction was added to 10 μL 50% ACN. This mixture was analysed using 
UPLC-HR-MS. A gradient of two mobile phases were used, mobile phase A: ultra-pure water 
with 0.1% formic acid (FA) and mobile phase B: ACN with 0.1% FA (see Table 14).  
Table 14: Mobile phase gradient used in UPLC-HR-MS analysis of active samples from the secondary 
anticancer screening. Mobile phase A: Ultra-pure water with 0.1 % FA, and mobile phase B: ACN with 0.1 % 
FA.  
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
Initial 0.55 80 20 
3.5 0.55 0 100 
5 0.55 0 100 
5.1 0.55 80 20 
 
The injection volume for each sample was 3 μL, and the run time was 6.50 min with a 0.55 
mL/min flow. Instrument parameters can be found in the appendix, see A1. The mass spectrum 
for each target compound was used to calculate an elemental composition. This elemental 
composition were used as a search input in Dictionary of Natural Products to determine if the 
target compounds were novel or previously reported compounds.  
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The sample AG-L-05 was refractionated (see section 3.6 “Refractionation of AG-L-05 with 
prep HPLC-MS”) and screened in a tertiary anticancer screening (see section 3.4.3 “Tertiary 
anticancer screening”) to better determine the compound(s) responsible for the observed 
anticancer activity in the secondary anticancer screening (see section 3.4.2 “Secondary 
anticancer screening”).  
3.6 Refractionation of AG-L-05 with prep HPLC-MS  
The material and equipment used for refractionation of sample AG-L-05 with prep HPLC-MS 
are listed in Table 15. 
Table 15: Materials and equipment used for refractionation of sample AG-L-05 with prep HPLC-MS.  
Materials/ Equipment Supplier 
 XTerra® Prep RP18 10μm 10*300 mm coloumn Waters, MA, USA 
Software: MassLynx 4.1 Waters, MA, USA 
600 Controller Waters, MA, USA 
2996 photodiodide array detector Waters, MA, USA 
3100 mass detector Waters, MA, USA 
2767 sample manager Waters, MA, USA 
Flow splitter Waters, MA, USA 
Prep degasser Waters, MA, USA 
515 HPLC pump Waters, MA, USA 
SC250 Express SpeedVac Concentrator  Thermo Fischer Scientific, MA, USA 
Heto PowerDry® PL9000 Freeze Dryer Thermo Fisher Scientific, MA, USA 
Acetonitrile, 34851 Sigma-Aldrich, MO, USA 
Formic acid, 56302 Sigma-Aldrich, MO, USA 
Methanol, 34860N Sigma-Aldrich, MO, USA 
Ultra-pure water Merck KGaA, Germany 
 
The sample AG-L-05 was prepared for refractionation with prep HPLC-MS by mixing 250 μL 
of sample (20 mg) with 50 μL 100% ACN. The injection volume was 280 μL (18.67 mg 
sample). A gradient of mobile phases, A: ultra-pure water with 0.1% FA and B: ACN with 0.1% 
FA, was used (Table 16). Instrument parameters can be found in the appendix, see A2.  
Table 16: Mobile phase gradient used during refractionation of sample AG-L-05 with prep HPLC-MS. Mobile 
phase A: Ultra-pure water with 0.1% FA, mobile phase B: ACN with 0.1% FA. Flow was 5 mL/min. 
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
initial 6 70 30 
30 6 30 70 




Total run time was 56 min and the eluting mobile phase was collected in 1 min fractions 
(collection time 40 min). This resulted in 40 collected fractions that were divided between three 
deep well plates, 2 mL per plate. The fractions were dried under vacuum and subsequently 
freeze-dried. The dried fractions were redissolved and analysed in a tertiary anticancer 
screening (see section 3.4.3 “Tertiary anticancer screening”).  
3.7 Isolation of target compounds from extract BI-L and AG-L using prep HPLC-MS 
The material and equipment used during isolation of target compounds from extract AG-L and 
BI-L are listed in Table 17. The instrument parameters can be seen in the appendix, A2. 
Isolation of target compounds was conducted on the crude extracts named after their originating 
species and the extraction method. Compounds were isolated from the organic extract of B.indet 
(BI-L) and the organic extract of A.gelatinosum (AG-L).  
Table 17: Materials and equipment used during isolation of target compounds using prep HPLC-MS.  
Materials/ Equipment Supplier 
 XTerra® Prep RP18 10μm 10*300 mm column Waters, MA, USA 
Atlantis® Prep dC18 10µm 10x250mm column Waters, MA, USA 
XSELECT™ CSH™ Phenyl-Hexyl Prep 5µm 10x250 column Waters, MA, USA 
XSELECT CSH™ Prep Fluoro-Phenyl 5µm 10x250 mm column Waters, MA, USA 
SunFire™ Prep C18 5µM 10x250mm column Waters, MA, USA 
Software: MassLynx 4.1 Waters, MA, USA 
600 Controller Waters, MA, USA 
2996 photodiodide array detector Waters, MA, USA 
3100 mass detector Waters, MA, USA 
2767 sample manager Waters, MA, USA 
Flow splitter Waters, MA, USA 
Prep degasser Waters, MA, USA 
515 HPLC pump Waters, MA, USA 
SC250 Express SpeedVac Concentrator  Thermo Fischer Scientific, MA, USA 
Heto PowerDry® PL9000 Freeze Dryer Thermo Fisher Scientific, MA, USA 
Acetonitrile, 34851 Sigma-Aldrich, MO, USA 
Formic acid, 56302 Sigma-Aldrich, MO, USA 
Methanol, 34860N Sigma-Aldrich, MO, USA 
Ultra-pure water Merck KGaA, Germany 
 
3.7.1 Pre-treatment of extract BI-L and AG-L (liquid-liquid partitioning) 
A liquid-liquid partitioning was performed on the organic extract of A.gelatinosum (AG-L) and 
B.indet (BI-L) (see section 3.2.1 “Extraction”). Approximately 1.5-2 g (1985.6 mg of AG-L 
and 1601.6 mg of BI-L) of organic extract was transferred to an Erlenmeyer flask and 50 mL 
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hexane was added. This mixture was poured into a separatory funnel, and the Erlenmeyer flask 
was washed twice with 50 mL hexane (added to the separatory funnel after each washing).  
To the mixture in the funnel, 150 mL 90% MeOH was added, and the mixture was allowed to 
separate into two distinct phases. Following collection of the MeOH phase, fresh 150 mL 90% 
MeOH was added to the separatory funnel. This was repeated twice. The MeOH phase was 
dried under vacuum. The resulting sample was kept at -23˚C until it was submitted to isolation 
using prep HPLC-MS (see Section 3.7.2 “Isolation of target compounds from extract BI-L (prep 
HPLC-MS)” and section 3.7.3 “Isolation of compounds from extract AG-L (prep HPLC-MS)”).  
3.7.2 Isolation of target compounds from extract BI-L (prep HPLC-MS) 
The observed bioactivity in the B.indet was detected in the aqueous extract BI-W, and 
dereplication pointed to compound with m/z 478.4 as a possible responsible compound for this 
bioactivity. The organic extract was investigated for the presence of this target compound, and 
because of the amount present of the compound with m/z 478.4 in this extract, it was decided 
to isolate compound m/z 478.4 from the organic extract BI-L instead of the aqueous extract BI-
W.  
The dried sample (1080mg) from liquid-liquid partitioning (see section 3.7.1 “Pre-treatment of 
extract BI-L and AG-L (liquid-liquid partitioning)”) was dissolved in 22 mL 100% MeOH 
(concentration 49.1 mg/mL). To determine the optimal purification conditions, 300 µL (14.70 
mg sample) of the dissolved sample was injected onto five different RP prep HPLC columns. 
A gradient of mobile phases was used (Table 18), named elution gradient 1. Mobile phase A: 
ultra-pure water with 0.1 % FA, and mobile phase B: ACN with 0.1% FA. Total run time was 
27 min. 
Table 18: A gradient of mobile phase A: ultra-pure water with 0.1 % FA, and mobile phase B: ACN with 0.1% 
FA was used (named elution gradient 1) during isolation of compounds utilising prep HPLC-MS. The flow was 
6 mL/min and total run time was 27 min. 
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
Initial 6 90 10 
20.00 6 30 70 
20.10 6 0 100 
25.00 6 0 100 




3.7.2.1 First and second round of separation using prep HPLC-MS (BI-L) 
Compounds BI-L-340.3, BI-L-665.6 and BI-L-478.4 were isolated using one or two rounds of 
HPLC separation (Table 19). The utilised elution gradients were versions of the elution gradient 
1 in Table 18. The column and gradient were changed for each round of HPLC separation. The 
injection volume was 500µL for the first round of HPLC separation and 100µL for the second 
round of HPLC separation. The compounds were collected in fractions using either mass 
triggered or time triggered fractionation. The resulting fractions were pooled and dried under 
vacuum, before being used in the next HPLC separation round, or finally before HR-MS and 
NMR analysis (see section 3.8 “HR-MS analysis of isolated compounds from extract BI-L and 
AG-L” and section 3.9 “NMR analysis of isolated compounds from extract BI-L and AG-L”). 
Table 19: The compounds BI-L-340.3, BI-L-665.6 and BI-L-478.4 were isolated under conditions described in 




Column Gradient Sample (mg) 
BI-L-340.3 
First Phenyl-hexyl 10-67 % B over 19 min, then 
100% B for 2 min 
3.35 
BI-L-665.6 
First Phenyl-hexyl 10-67 % B over 19 min, then 
100% B for 2 min 
2.25 
Second Fluoro-phenyl 10-58 % B over 16 min, then 
100% B for 2min 
0.60 
BI-L-478.4 
First Phenyl-hexyl 10-67 % B over 19 min, then 
100% B for 2 min 
5.30 
Second Fluoro-phenyl 10-64 % B over 18 min, then 
100% B for 2min 
0.90 
 
3.7.3 Isolation of compounds from extract AG-L (prep HPLC-MS) 
The dried AG-L sample (1400 mg) from liquid-liquid partitioning (see section 3.7.1 “Pre-
treatment of extract BI-L and AG-L (liquid-liquid partitioning)”) was dissolved in 31 mL 100% 
MeOH. To determine the optimal purification conditions, 300 µL (13.55 mg sample) of the 
dissolved sample was injected onto five different RP prep HPLC columns. The utilised mobile 
phase gradient can be seen in Table 18 (elution gradient 1). Mobile phase A: ultra-pure water 
with 0.1 % FA, and mobile phase B: ACN with 0.1% FA. Total run time was 27 min.  
3.7.3.1 First, second and third round of separation using prep HPLC-MS (AG-L) 
Compounds AG-L-465.3, AG-L-449.4 and AG-L-541.4 were isolated using three rounds of 
HPLC separations (Table 20). The gradients used was a version of elution gradient 1 in Table 
18. The column and elution gradients were changed for each round of HPLC separation. The 
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injection volume in the first round of HPLC separation was 700 µL, 70-150 µL (100µL for AG-
L-05-465.3, 70µL for AG-L-05-449.4 and 150 µL for AG-L-05-541.4) for the second round 
and 100 µL for the third round of HPLC separation. Compounds were collected in fractions 
using either mass triggered or time triggered fractionation. The resulting fractions were pooled 
and dried under vacuum, before being used in the next HPLC separation round or finally before 
HR-MS and NMR analysis (see section 3.8 “HR-MS analysis of isolated compounds from 
extract BI-L and AG-L” and section 3.9 “NMR analysis of isolated compounds from extract 
BI-L and AG-L”).  
Table 20: The compounds AG-L-05-465.3, AG-L-05-449.4 and AG-L-05-541.4 were isolated under conditions 








First Phenyl-hexyl 10-70% B over 20 min, then 
100% B for 1 min 
12.50 
Second Fluoro-phenyl 10-46% B over 12 min, then 
100% B for 1 min 
4.20 
Third Atlantis® 10-52% B over 14 min, then 
100% B for 1 min 
1.25 
AG-L-05-449.4 
First Phenyl-hexyl 10-70% B over 20 min, then 100 
% B for 1 min 
33.60 
Second Fluoro-phenyl 10-52% B over 14 min, then 
100% B for 1 min 
14.20 
Third Xterra® 10-61% B over 17 min, then 
100% B for 1 min 
5.47 
AG-L-05-541.4 
First Phenyl-hexyl 10-70% B over 20 min, then 100 
% B for 1 min 
21.75 
Second SunFire™ 10-76% B over 22 min, then 
100% B for 1 min 
6.10 
Third Atlantis® 10-76% B over 22 min, then 
100% B for 1 min 
3.03 
 
3.8 HR-MS analysis of isolated compounds from extract BI-L and AG-L 
The material and equipment used in HR-MS analysis for isolated compounds from the extract 
BI-L (section 3.7.2 “Isolation of target compounds from extract BI-L (prep HPLC-MS)”) and 
AG-L (section 3.9 “NMR analysis of isolated compounds from extract BI-L and AG-L”) are 
shown in Table 21.  
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Table 21: The material and equipment used in UPLC-QToF-MS analysis of the isolated compounds from 
extract AG-L and BI-L.  
Materials/Equipment Supplier 
ACQUITY UPLC® PDA Detector Waters, Milford, MA, USA 
ACQUITY UPLC® Column Manager Waters, Milford, MA, USA 
ACQUITY UPLC® I-Class Sample Manager FTN Waters, Milford, MA, USA 
ACQUITY UPLC® I-Class Binary Solvent Manager Waters, Milford, MA, USA 
Vion IMS QToF Waters, Milford, MA, USA 
ACQUITY UPLC® BEH C18 1.7µM 2.1*100m column Waters, Milford, MA, USA 
Software: UNIFI Waters, Milford, MA, USA 
Methanol LC-MS Ultra CHROMASOLV®, 14262 Thermo Fisher Scientific, MA, USA 
LiChrosol® Acetonitrile (hypergrade for LC-MS), 1.00029 Merck KGaA, Germany 
Formic Acid ULC/MS 99%, 069141 Biosolve B.V., Netherland 
Ultra-pure water  Merck KGaA, Germany 
 
The samples were dissolved and diluted in 80% MeOH, and injected onto the UPLC column 
(injection volume 1 µL). A gradient of mobile phases, A: ultra-pure water with 0.1% FA, and 
B: ACN with 0.1% FA, was used (see Table 22). For instrument parameters, see appendix A3.  
Table 22: Mobile phase gradient used in HR-MS analysis of isolated compounds from extract AG-L and BI-L. 
Mobile phase A: ultra-pure water with 0.1% FA, mobile phase B: ACN with 0.1% FA.  
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
0.00 0.50 90.0 10.0 
7.00 0.50 0.0 100.0 
8.00 0.50 0.0 100.0 
 
3.9 NMR analysis of isolated compounds from extract BI-L and AG-L 
Johan Isaksson at the Department of Chemistry at UiT The Arctic University of Norway 
performed this procedure, as well as the interpretation of the data. 
All spectra were acquired on a Bruker Avance III HD spectrometer operating at 599.90 MHz 
for protons, equipped with an inverse detected cryo-probe enhanced for 1H, 13C and 2H.  
The NMR samples (see section 3.8 “HR-MS analysis of isolated compounds from extract BI-L 
and AG-L” and section 3.9 “NMR analysis of isolated compounds from extract BI-L and AG-
L”) were prepared by dissolving the sample in 500 µL DMSO (as described in Table 23). The 
sample was transferred into a 5mm disposable tube. Experiments were typically acquired using 
gradient selected adiabatic versions where applicable. All experiments were acquired using 




Table 23: Isolated compounds were analysed in DMSO as described in this table.  
Isolated compound Weight (mg) DMSO (µL) 
AG-L-05-465.3 1.25 500  
AG-L-05-449.4 5.47 500  
AG-L-05-541.4 3.03 500  
BI-L-05-340.3 3.48 500  
BI-L-05-665.59 0.6 500  






4.1 Primary anticancer screening  
Flash fractions analysed in the fall of 2015 causing remaining cell survival of the malignant cell 
line A2058 to drop below 50% in the primary anticancer screening, were chosen for further 
examination in this thesis. Table 24 shows the result from the primary anticancer screening for 
the 19 fractions (eight different invertebrates) that were chosen for further examination in this 
thesis. An overview of sample names can be seen on page III.  
Table 24: The results of the 19 flash fractions screened in the fall of 2015 that were found to inhibit cell survival 
of A2058 in an ongoing anticancer screening campaign at Marbio. Cell survival (%) was determined by the MTS 
assay after 72 hours of exposure to the samples. 
Sample Cell survival (%) Sample Cell survival (%) 
ML-W-05 0 PI-L-06 10 
ML-W-06 0 PI-W-06 49 
ML-W-07 3 AG-W-04 11 
ML-L-04 44 AG-W-05 1 
ML-L-05 0 AG-L-05 17 
ML-L-06 6 SR-W-05 2 
ML-L-07 12 AB-L-07 34 
BI-W-04 50 NP-L-05 0 




4.2 Secondary anticancer screening 
To confirm the results obtained in the primary anticancer screening, and to avoid further work 
with false positive samples, a secondary anticancer screening (A2058) was conducted. The 
fractions were also screened against non-malignant lung fibroblasts (MRC-5) to investigate the 
flash fraction`s toxicity against normal human cells.  
4.2.1 Mycale (Mycale) lingua (ML) 
Seven fractions from M.lingua were screened in the secondary anticancer screening and the 
results can be seen in Figure 9. All seven fractions showed anticancer activity in the secondary 
screening. The fraction ML-L-04 showed less anticancer activity towards A2058 than the other 
fractions from the organic extract of M.lingua. Furthermore, many of the fractions also showed 
a higher activity against A2058 compared to MRC-5. A dose-response effect could be observed 
for some of the fractions (exemplified by fraction ML-W-05 in Figure 9). As the activity of the 
ML-L-04 was weaker compared to its adjacent fractions and the fractions of the water extract, 
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this fraction was not submitted for dereplication. All the other fractions were dereplicated in an 
attempt to identify the compounds causing the observed bioactivity.  
 
Figure 9: Results from the secondary anticancer screening of fractions from M.lingua. The fractions were 
screened against the A2058 and MRC-5 cell line. The cell survival (%) was determined by the MTS assay after 72 
hours of exposure to the flash fractions and the values are means of two parallel fractions. Concentration points 
with no apparent bar had 0% cell survival. 
4.2.2 Bryozoa indet (BI) 
Results from the secondary anticancer screening of fractions from B.indet can be seen in Figure 
10. Fraction BI-W-05 showed activity against the A2058 and MRC-5 cell line. The activity of 
this fraction was confirmed, and the fraction was therefore submitted for dereplication using 
UPLC-HR-MS. Fractions BI-W-04 and BI-W-06 were not deemed active against the A2058 
and MRC-5 cell line. Therefore, no further work was done with these fractions. 
 
Figure 10: Results from the secondary anticancer screening of fractions from B.indet.  The fractions were 
screened against the A2058 and MRC-5 cell line. The cell survival (%) was determined by the MTS assay after 72 
hours of exposure to the fractions, and the values are means of parallel fractions. Concentration points with no 
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4.2.3 Porifera indet (PI) 
Results from the secondary anticancer screening of fractions from P.indet can be seen in Figure 
11. The fraction PI-L-06 showed activity against the A2058 and the MRC-5 cell line. 
Furthermore, a dose-response effect could also be observed for this fraction. The activity of this 
fraction was confirmed, and the fraction was submitted for dereplication using UPLC-HR-MS. 
The fraction PI-W-06 showed a weak activity towards A2058, but was deemed not active in the 
secondary anticancer screening. No further work was done with this fraction.     
 
Figure 11: Results from the secondary anticancer screening of fractions from P. indet. The fractions were 
screened against the A2058 and MRC-5 cell line. The cell survival (%) was determined by the MTS assay after 72 
hours of exposure to the fractions, and the values are means of parallel fractions.  
4.2.4 Alcyonidium gelatinosum (AG) 
In Figure 12, results from the secondary anticancer screening of fractions from A.gelatinosum 
are shown. The fraction AG-L-05 showed activity against the A2058 and MRC-5 cell line. 
Furthermore, a dose-response effect could be observed for both of the exposed cell lines. The 
fraction was submitted for dereplication using UPLC-HR-MS. The fractions AG-W-04 and 






















Figure 12: Results from the secondary anticancer screening of fractions from A.gelatinosum.  The fractions 
were screened against the A2058 and MRC-5 cell line. The cell survival (%) was determined by the MTS assay 
after 72 hours of exposure to the fractions, and the values are means of parallel fractions. Concentration points 
with no apparent bar had 0% cell survival. 
4.2.5 Styela rustica (SR), Astarte borealis (AB), Nuculana pernula (NP) and 
Strongylocentrotus droebachiensis (SD) 
Results from the secondary anticancer screening of fractions from S.rustica, A.borealis, 
N.pernula and S.droebachiensis are shown in Figure 13. Fractions SR-W-05, AB-L-07, NP-L-
05 and SD-L-01 were deemed not active against A2058. Consequently, no further work was 
done with these fractions.   
 
Figure 13: Results from the secondary anticancer screening of fractions from S.rustica (A), A.borealis (B), 
N.pernula (C) and S.droebachiensis (D). The fractions were screened against the A2058 and MRC-5 cell line. 
Cell survival (%) was determined by the MTS assay after 72 hours of exposure to the fractions, and the values are 
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4.2.6 Summary anticancer screening 
Based on the results from the secondary anticancer screening, the fractions that were chosen for 
dereplication with UPLC-HR-MS were  
 ML-W-05, ML-W-06 and ML-W-07   
 ML-L-05, ML-L-06 and ML-L-07 
 BI-W-05  
 AG-L-05  
 PI-L-06  
4.3 Dereplication 
Fractions with a positive result in the secondary anticancer screening, as well as the fraction 
eluting directly before and directly after the active fraction(s), were analysed with UPLC-HR-
MS. The results from this analysis were processed in an attempt to determine possible active 
compound(s). This was done by trying to identify compound(s) found exclusively, or in a 
significantly higher concentration, in the active fraction. An elemental composition was 
calculated for the target compounds, and database searches were performed to assess if the 
compound was novel or previously reported.  
4.3.1 Mycale (Mycale) lingua (ML) 
In the active fractions, ML-W-05, ML-W-06 and ML-W-07, a peak with m/z 482.35 were 
detected (marked with a black arrow for ML-W-05 in Figure 14). The elemental composition 
was calculated, C23H48NO7P, and this gave a hit with a phosphocholine when searching in the 
Dictionary of Natural Products. Phosphocholines are compounds that are known to interact with 
the cell membrane and are not considered interesting for drug development (Hansen & 





Figure 14: UPLC-HR-MS Base peak intensity (BPI) chromatograms of fractions ML-W-04, W-05, W-06, W-
07 and W-08. The fractions were injected onto a Waters Aquity UPLC ® (2.1x100 mm, 1.7 μm) column. A gradient 
of ultra-pure water with 0.1% FA and ACN with 0.1% FA was used with a flow rate of 0.5 mL/min (20-100% ACN 
with 0.1% FA over 3.5 min, then 100 % ACN over 1.5 min). Fractions marked “I” were inactive and “A” were 
active in the secondary anticancer screening. A phosphocholine was detected in the three active fractions (marked 
with a black arrow in fraction ML-W-05). 
Similar to ML-W-05, ML-W-06 and ML-W-07, a peak with m/z 482.35 was detected in the 
active fractions ML-L-05, ML-L-06 and ML-L 07 (Figure 15, marked with a black arrow in 
fraction ML-L-05). The elemental composition was calculated to be the same as the peak with 
m/z 482.35 in the active fractions of the aqueous extract of this invertebrate. Due to the presence 




Figure 15: UPLC-HR-MS BPI chromatograms of fractions ML-L-04, -L-05, -L-06, -L-07 and -L-08. The 
fractions were injected onto a Waters Aquity UPLC ® (2.1x100 mm, 1.7 μm) column. A gradient of ultra-pure 
water with 0.1% FA and ACN with 0.1% FA was used with a flow rate of 0.5 mL/min (20-100% ACN with 0.1% 
FA over 3.5 min, then 100 % ACN over 1.5 min). Fractions marked “I” were inactive and “A” were active in the 
secondary anticancer screening. A phosphocholine was detected in the active fractions (marked with a black arrow 
in fraction ML-L-05). 
4.3.2 Bryozoa indet (BI) 
In the active fraction BI-W-05, one compound in particular (labelled BI-L-478.4) stood out in 
the resulting chromatogram and was only observed in the active fraction (Figure 16-left). As a 
result, this compound was believed to be responsible for the observed bioactivity in the 
secondary anticancer screening. The mass spectrum for this compound can be seen in Figure 
16 (right). The calculated elemental composition for BI-L-478.4 was C25H51NO7. This formula 
gave no hits in Dictionary of Natural Products. The compound was submitted for isolation using 
prep HPLC-MS and was named BI-L-478.4. This name was used because the compound was 
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isolated from the organic extract of B.indet, where it was present in a larger amount than in the 
aqueous extract.    
 
Figure 16: Left) UPLC-HR-MS BPI chromatograms of active fraction BI-W-05, and inactive fractions BI-W-
04 and BI-W-06. The fraction was injected onto a Waters Aquity UPLC ® (2.1x100 mm, 1.7 μm) column. A 
gradient of ultra-pure water with 0.1% FA and ACN with 0.1% FA was used with a flow rate of 0.5 mL/min (20-
100% ACN with 0.1% FA over 3.5 min, then 100 % ACN over 1.5 min). Compound BI-L-478.4  was exclusively 
found in the active fraction. Right) Mass spectrum for BI-L-478.4. The calculated elemental composition for BI-
L-478.4 was C25H51NO7. This formula gave no hits in Dictionary of Natural Products. 
4.3.3 Porifera indet (PI) 
The active fraction PI-L-06 was analysed without comparison with the inactive fractions (PI-
L-05 and PI-L-07) because there was no more sample available of these fractions. One peak 
stood out in the resulting chromatogram (Figure 17-left), highlighted as ianthelline, and was 
believed to be responsible for the observed bioactivity. Its elemental composition was 
calculated to be C15H17Br2N5O3. This elemental composition gave a hit with iantheline when 
searching in Dictionary of Natural Products. Ianthelline has previously been isolated from the 
sponge Stryphnus fortis and its structure is published (Shearman, Myers, Beale, Brenton, & 
Ley, 2010). In addition, its bioactivity has been thoroughly investigated at Marbio (Hanssen, 
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Andersen, et al., 2012; Hanssen et al., 2014). As a consequence of this extensive previous work, 
no further work was conducted with this fraction.  
 
Figure 17: Left) UPLC-HR-MS BPI chromatograms of fraction PI-L-06. The fraction was injected onto a Waters 
Aquity UPLC ® (2.1x100 mm, 1.7 μm) column. A gradient of ultra-pure water with 0.1% FA and ACN with 0.1% 
FA was used with a flow rate of 0.5 mL/min (20-100% ACN with 0.1% FA over 3.5 min, then 100 % ACN over 1.5 
min). Ianthelline was believed to be responsible for the observed bioactivity. Right) Mass spectrum for the 
compound marked ianthelline in fraction PI-L-06. The calculated elemental composition for this compound was 
C15H17Br2N5O3. This elemental composition gave a hit with ianthelline in Database of Natural Products. 
Consequently, no further work was done with this fraction. 
4.3.4 Alcyonidium gelatinosum (AG) 
In the active fraction AG-L-05, it was difficult to determine compound(s) responsible for the 
observed bioactivity (Figure 18). As a consequence of this, this fraction was further fractionated 




Figure 18: UPLC-HR-MS BPI chromatograms of fraction AG-L-05. The fraction was injected onto a Waters 
Aquity UPLC ® (2.1x100 mm, 1.7 μm) column. A gradient of ultra-pure water with 0.1% FA and ACN with 0.1% 
FA was used with a flow rate of 0.5 mL/min (20-100% ACN with 0.1% FA over 3.5 min, then 100 % ACN over 1.5 
min). In this fraction, compound(s) responsible for the observed bioactivity could not be determined solely based 
on these results. 
4.3.4.1 Refractionation of AG-L-05 using prep HPLC-MS 
Flash fraction 5 of the organic extract of A.gelatinosum was injected onto a RP C18 column 
and the eluting mobile phase was collected in 1 min fractions. This resulted in 40 collected 
fractions that were dried, re-dissolved and screened for activity against A2058. The resulting 




Figure 19: BPI chromatogram from the refractionation of fraction AG-L-05 with prep HPLC-MS. The fraction 
was injected onto a Waters XTerra® Prep RP18 (10μm 10x300 mm) column. A gradient of ultra-pure water with 
0.1% FA and ACN with 0.1% FA was used with a flow rate of 6 mL/min (30-70% ACN with 0.1% FA over 30 min, 
then 70-100% ACN with 0.1% FA over 10 min). During this refractionation, 40 1 min fractions were collected for 
further analysis in a tertiary anticancer screening.  
Anticancer activity in the refractionated fraction AG-L-05 
The results from the tertiary anticancer screening against A2058 can be seen in Figure 20. 
Fractions 15, 17-22, 24, 27, 28, 33, 34, 36 and 37 were found to result in cell survival lower 
than 50%, and these fractions were therefore deemed active.  
 
Figure 20: Results from tertiary anticancer screening of the 40 collected fractions from the refractionation of 
fraction AG-L-05. The fractions were screened against A2058. Cell survival was determined by the MTS assay 




















Dereplication of the active fractions from the refractionated AG-L-05 
The results from the tertiary anticancer screening were compared to the chromatogram from the 
refractionation of the fraction AG-L-05 (Figure 21) in an attempt to identify bioactive 
compounds. Based on the results in Figure 21, compounds were selected as possible candidates 
for isolation. Extracted ion chromatograms (from Figure 19) for the target compounds were 
generated and mass spectra were analysed to calculate the elemental composition of the target 
compounds. The green bars in Figure 21 highlight the fractions that contained the compounds 
nominated for isolation. 
 
Figure 21: The results from the tertiary anticancer screening of the 40 fractions from refractionation of fraction 
AG-L-05 overlaid the prep HPLC-MS chromatogram from when the fractions were produced. The green bars 
highlights the fractions that contained the compounds nominated for isolation. Compounds from fraction 11, 15, 
19-22 and 24 selected for isolation. 
Fraction 11 
A compound found in fraction 11 was submitted for isolation even though it did not result in 
significant inhibition of cell survival. This was done because this target compound (m/z 449.4) 
was believed to be structurally related to target compound m/z 465.3 (see Fraction 24). These 
two compounds differed with 16 mass units, indicating that m/z 449.4 (no elemental 





Fraction AG-L-05-15 gave 14% cell survival of A2058. In this fraction (time 14-15 min in the 
chromatogram) two clear peaks were visible. The m/z of these peaks were 411.4 and 431.4 
(Figure 22-left). Only one of these compounds, m/z 431,4, could however be found in the 
chromatogram from the UPLC-HR-MS analysis of AG-L-05. The mass spectrum for m/z 431.4 
can be seen in Figure 22-right. The elemental composition of this compound was calculated to 
be C28H39N4.  A search in Dictionary of Natural Products gave no hits with this elemental 
composition. This compound was selected for isolation. In addition, the compound with m/z 
411.4 was also selected for isolation. The compounds were named AG-L-431.4 and AG-L-
411.1.  
 
Figure 22: Left) Ion chromatogram for the compound from fraction 15 that was believed to be responsible for 
the observed bioactivity in the tertiary anticancer screening. Right) Mass spectrum for this compound, the 
calculated elemental composition was C28H38N4. A search in Dictionary of Natural Products gave no hits with this 
elemental composition. 
Fractions 19-21 
Fractions 19, 20 and 21 gave 14%, 6% and 8% remaining cell survival, respectively, of  A2058. 
Two clear peaks were visible in these fractions (time 19 to 20.5 min in the chromatogram), and 
these compounds had identical masses, m/z 483.3 (Figure 23-left). These compounds were 
found in the resulting chromatogram from the UPLC-HR-MS analysis of AG-L-05 and the mass 
spectrum for m/z 483.3 can be seen in Figure 23-right. Both compounds were calculated to have 
the same elemental composition: C30H34N4O2. A search in Dictionary of Natural Products gave 
no hits with this elemental composition. This compound, named AG-L-483.3 was submitted 




Figure 23: Left) Ion chromatogram for the compounds from fraction 19-21 that were believed to be responsible 
for the observed bioactivity in the tertiary anticancer screening. Right) Mass spectrum for this compound, the 
calculated elemental composition was C30H34N4O2. A search in Dictionary of Natural Products gave no hits with 
this elemental composition. 
Fraction 22 
Fraction 22 gave 2% remaining cell survival in the tertiary anticancer screening. In this fraction 
(time 21-22 min in the chromatogram) a big peak was visible (Figure 24-left). The m/z for this 
compound was 437.4. This compound was found in the resulting chromatogram from the 
UPLC-HR-MS analysis of AG-L-05 and the mass spectrum for m/z 437.4 can be seen in Figure 
24-right. The elemental composition of this compound was calculated to be C27H27N4F. A 
search in Dictionary of Natural Products gave no hits with this elemental composition. The 
compound, named AG-L-437.4 was submitted for isolation.   
 
Figure 24: Left) Ion chromatogram for the compound from fraction 22 that was believed to be responsible for 
the observed bioactivity. Right) Mass spectrum for this compound, the calculated elemental composition was 




Fraction AG-L-05-24 gave 3% remaining cell survival in the tertiary anticancer screening. In 
this fraction (time 23-24 min in the chromatogram), two clear peaks were visible (Figure 25-
left).  These peaks had identical masses, m/z 465.3. These compounds were found in the 
resulting chromatogram from the UPLC-HR-MS analysis of AG-L-05. The mass spectrum for 
m/z 465.3 can be seen in Figure 25-right. Using Mass Lynx software, the elemental 
compositions for these compounds were calculated. Both compounds were calculated to have 
the same elemental composition: C29H36O5. A search in Dictionary of Natural Products gave 
hits with four different compounds with the same empirical formula. Despite this, it was decided 
to isolate the compound, named AG-L-465.3, using prep HPLC-MS.   
 
Figure 25: Left) Ion chromatogram for the compound from fraction 24 that was believed to be responsible for 
the observed bioactivity. Right) Mass spectrum for this compound, the calculated elemental composition was 
C29H36O5. A search in Dictionary of Natural Products gave hits with four different compounds with the same 
empirical formula.  
4.3.5 Summary dereplication 
In total, seven compounds were nominated for isolation using prep HPLC-MS: A compound 
with m/z 478.4 in sample BI-W-05 and six compounds from sample AG-L-05. The target 
compound in BI-W-05 was isolated from the organic extract of B.indet and was therefore named 
BI-L-478.4. An overview of the target compounds and target compound names can be seen in 




Table 25: Compounds nominated for isolation from the fractions BI-W-05 and AG-L-05. In total, seven 
compounds were nominated for isolation using prep HPLC-MS. 
Fraction name Target compound (m/z) Name 





483.3 (1) AG-L-483.4 (1) 




4.4 Prep HPLC-MS separation of target compounds from the organic extract BI-L 
To isolate compounds from fractions that showed anticancer activity in the secondary 
anticancer screening, prep HPLC-MS purification was conducted on the organic extract BI-L.  
4.4.1 Crude separation of the target compounds from BI-L 
Five columns with different surface chemistry were evaluated for use in the first round of HPLC 
separation (for chromatograms see appendix, A4). Based on these results, the phenyl-hexyl 
column was chosen for the first round of HPLC separation (Figure 26) and the fractions were 
collected by time triggered fractionation. The compound in fraction 4 was selected for isolation 
based on the results from the secondary anticancer screening (Figure 10) and dereplication 
(Figure 16). The other remaining compounds were included in the isolation due to the amount 
present in the fraction and the possibility of achieving a pure compound within the time frame 
of this thesis. The target compounds, and the weight of the resulting dried fractions, were as 
followed: 
Fraction 1: BI-L-340.3  (3.35 mg)  
Fraction 2: BI-L-369.3  (0.85 mg)  
Fraction 3: BI-L-665.6  (2.25 mg)  




Figure 26: BPI chromatogram for the first round of HPLC separation of target compounds from the organic 
extract BI-L. The compounds were separated using a phenyl-hexyl column. An elution gradient of ultra-pure water 
with 0.1 % FA and ACN with 0.1 % FA was used with a flow rate of 6 mL/min (10-67 % ACN with 0.1% FA over 
19 min, then 100% ACN with 0.1% FA for 2min). Fractions 1-4 were collected by time triggered fractionation. 
The green boxes show the fractions that were selected for further purification (fraction 3 and 4). Fraction 1 was 
submitted for NMR analysis after this crude separation.  
It was decided to further purify BI-L-665.6 from fraction 3 and BI-L-478.4 from fraction 4. In 
addition, compound BI-L-340.3 from fraction 1 was submitted for NMR analysis after this 
crude separation because of the limited amount isolated of this compound.  
4.4.2 Purification of BI-L-665.6 from fraction 3 
To remove impurities from compound BI-L-665.6, a version of elution gradient 1and the fluoro-
phenyl column were used. Fraction collection was triggered by retention time and the BPI 
chromatogram from this isolation can be seen in Figure 27. This isolation resulted in 0.6 mg of 




Figure 27: BPI chromatogram from the second round of HPLC separation of BI-L-665.6 from the organic 
extract BI-L. The collected fraction from the first round of HPLC separation was further purified using a fluoro-
phenyl column and a shortened version of elution gradient 1 (10-58 % ACN with 0.1 % FA over 16 min, then 100% 
ACN with 0.1% FA for 2min). This isolation resulted in 0.6 mg of compound.  
4.4.3 Purification of BI-L-478.4 from fraction 4 
To remove impurities from compound BI-L-478.4, a version of elution gradient 1 and a fluoro-
phenyl column were used. Fraction collection was triggered retention time and the BPI 
chromatogram from this isolation can be seen in Figure 28. This isolation resulted in 0.9 mg of 
compound and it was therefore decided to not purify the compound further.  
 
Figure 28: BPI chromatogram of the second round of HPLC separation of BI-L-478.4 from the organic extract 
BI-L. The collected fraction from the first round of HPLC separation was further purified by using a fluoro-phenyl 
column and a shortened version of elution gradient 1 (10-64 % ACN with 0.1 % FA over 18 min, then 100% ACN 
with 0.1% FA for 2min). The isolation resulted in 0.9 mg of compound.  
4.5 Prep HPLC-MS separation of target compounds from the organic extract AG-L 
To isolate compounds from fractions that showed anticancer activity in the tertiary anticancer 
screening, purification utilising prep HPLC-MS was conducted on the organic extract AG-L.  
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4.5.1 Crude separation of the target compounds 
Five columns with different surface chemistry were evaluated for use in the first round of HPLC 
separation (for chromatograms, see appendix A5). Based on these results the phenyl-hexyl 
column was chosen for the first round of HPLC separation (Figure 29) and the compounds were 
collected by time triggered fractionation. The target compound in each fraction was nominated 
for isolation based on the results from the bioactivity screening and dereplication, as previously 
explained (Figure 21). The target compounds and the weight of the resulting dried fractions 
were as followed: 
Fraction 1: AG-L-465.3   (12.15 mg)  
Fraction 2: AG-L-449.4   (33.6 mg)  
Fraction 3: AG-L-411.4   (56.7 mg)  
Fraction 4: AG-L-431.4   (33.9 mg)  
Fraction 5: AG-L-483.4 (1)   (21.75 mg)  
Fraction 6: AG-L-483.4 (2)  (32.8 mg)  
Fraction 7: AG-L-437.4   (38.8 mg) 
 
Figure 29: BPI chromatogram for the first round of HPLC separation of target compounds from the organic 
extract AG-L. The compounds were separated using a phenyl-hexyl column. An elution gradient of ultra-pure 
water with 0.1% FA and ACN with 0.1% FA was used with a flow rate of 6 mL/min (10-70% ACN with 0.1 % FA 
over 20 min, then 100 % ACN with 0.1% FA for 1 min). Fractions 1-7 were collected by time triggered 
fractionation. The green boxes show the fractions that were selected for further purification. 
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It was decided to further purify AG-L-465.3 from fraction 1, AG-L-449.4 from fraction 2 and 
AG-L-541.4 from fraction 5 (AG-L-541.4 was present in fraction 5 from the first HPLC 
separation round).  
4.5.2 Purification of AG-L-465.3 from fraction 1 
To remove impurities from compound AG-L-465.3 in fraction 1, a version of elution gradient 
1, and the fluoro-phenyl and Atlantis® column were used. Fraction collection was triggered by 
mass and the BPI chromatograms from these isolations can be seen in Figure 30. This isolation 
resulted in 1.25 mg of isolated compound after the third round of HPLC separation. 
 
Figure 30: BPI chromatogram of the second and third round of HPLC separation of AG-L-465.3 from the 
organic extract AG-L. A) The collected fraction from the first round of HPLC separation was further purified by 
using a fluoro-phenyl column and a shortened version of elution gradient 1 (10-46% ACN with 0.1% FA over 12 
min, then 100% ACN with 0.1% FA for 1 min). B) In the third round of HPLC separation, the collected fraction 
from the second round of HPLC separation was further purified by using an Atlantis® column and a shortened 
version of elution gradient 1 (10-52% ACN with 0.1% FA over 14 min, then 100% ACN with 0.1% FA for 1 min). 
This isolation resulted in 1.25 mg of isolated compound after three rounds of HPLC separation. 
4.5.3 Purification of AG-L-449.4 from fraction 2 
To remove impurities from compound AG-L-449.4 in fraction 2, a version of elution gradient 
1, and the fluoro-phenyl and XTerra® column were used. Fraction collection was triggered by 
time (second round) or mass (third round), and the BPI chromatograms from these isolations 
can be seen in Figure 31. This isolation resulted in 5.47 mg of isolated compound after the third 




Figure 31: BPI chromatograms of the second and third round of HPLC separation of AG-L-449.4 from the 
organic extract AG-L. A) The collected fraction from the first round of HPLC separation was further purified by 
using a fluoro-phenyl column and a shortened version of elution gradient 1 (10-52% ACN with 0.1% FA over 14 
min, then 100% ACN with 0.1% FA for 1 min). B) The collected fraction from the second round of HPLC 
separation was further purified by using XTerra® column and a shortened version of elution gradient 1 (10-61% 
ACN with 0.1% FA over 17 min, then 100% ACN with 0.1% FA for 1 min). This isolation resulted in 5.47 mg of 
isolated compound. 
4.5.4 Purification of AG-L-541.4 from fraction 5 
Fraction 5 from the first round of HPLC separation was collected in an attempt to start isolation 
of compound AG-L-483.4 (1). In addition to this compound, fraction 5 contained a compound 
with m/z 541.4 (named AG-L-541.4). It was decided to further purify AG-L-541.4 from this 
first round of HPLC separation. To remove impurities from AG-L-541.4, a version of elution 
gradient 1, and the Sunfire™ and Atlantis® column were used. Fraction collection was 
triggered by time and the BPI chromatograms from these HPLC separations can be seen in 
Figure 32. This isolation resulted in 3.03 mg of isolated compound after the third round of 
HPLC separation. 
 
Figure 32: BPI chromatograms of the second and third round of HPLC separation of AG-L-541.4 from the 
organic extract AG-L. A) The collected fraction from the first round of HPLC separation was further purified by 
using a SunFire™ column and a shortened version of elution gradient 1 (10-76% ACN  with 0.1% FA over 22 
min, then 100% ACN with 0.1% FA for 1 min). B) The collected fraction from the second round of HPLC 
separation was further purified by using a Atlantis® column and a shortened version of  elution gradient 1 (10-
76% ACN with 0.1% FA over 22 min, then 100% ACN with 0.1% FA for 1 min). This isolation resulted in 3.03 mg 
of isolated compound. 
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4.5.5 Summary isolation 
Three isolated compounds from BI-L and three isolated compounds from AG-L were submitted 
for structure elucidation employing NMR and HR-MS analyses. Table 26 shows the isolated 
compounds, as well as the calculated elemental composition and criteria for why the compounds 
were chosen for isolation. Some of these compounds were included in the isolation due to the 
amount of compound present (an elemental composition was not calculated for these 
compounds).  
Table 26: Overview of isolated compounds from the extracts BI-L and AG-L. In total, six compounds were 
isolated and submitted for structure elucidation employing NMR and HR-MS, A calculated elemental composition 
can be seen for AG-L-465.3 and BI-L-478.4.  






Criteria for isolation 
BI-L 
340.3 - 3.35 Amount of compound 
478.4 C25H51NO7 0.9 Bioactivity 
665.6 - 0.6 Amount of compound 
AG-L 
465.3 C29H36O5 1.25 Bioactivity 
449.4 Assumed to be C29H36O4 5.47 Believed to be 
structurally related to 
AG-L-465.4 
541.4 - 3.03 Amount of compound 
 
4.6 NMR analysis of isolated compounds from BI-L and AG-L  
The isolated compounds BI-L-340.3 (one round of HPLC separation), BI-L-478.4 (two rounds 
of HPLC separation) and BI-L-665.6 (two rounds of HPLC separation) from the extract BI-L, 
as well as AG-L-465.3, AG-L-449.4 and AG-L-541.4 (three rounds of HPLC separation for 
each compound) from the extract AG-L, were analysed using HR-MS and NMR. The structure 
was elucidated for BI-L-665.6, AG-L-465.3 and AG-L-449.4, while the other compounds in 
Table 26 were not purified enough to enable elucidation of the structure.  
4.6.1 BI-L-665.6 
The structure of compound BI-L-665.6 can be seen in Figure 33. The purity of the isolated 
product was 70-85%. The structure seen in Figure 33 was the most probable structure based on 
data simulations, but it was not possible to rule out other possible structures. The hydroxyl 
(OH)-group at carbon 19 could also be placed on carbon 20. The OH-group placed at carbon 
28 could be placed anywhere from carbon 24 to carbon 31. The molecular formula of the 
compound was C37H69O8. No hits in Dictionary of Natural Products or in SciFinder were 





Figure 33: Molecular structure of BI-L-665.6 and atomic numbering of the molecule. The molecular formula 
was C37H69O8. 
4.6.2 AG-L-465.3 (Pon A) 
The structure for compound AG-L-465.3 can be seen in Figure 34. The purity of the isolated 
product was ~90 % and the chemical formula was C27H44O6. The structure elucidation shows 
that the isolated product was Pon A. The calculated elemental composition from dereplication 
of this compound did not match the molecular formula for Pon A.  
 
Figure 34: Molecular structure of compound AG-L-465.3 and atomic numbering of the molecule. The structure 
elucidation shows that the isolated product is a steroid called Pon A.  
4.6.3 AG-L-449.4 (Dehydroxy-Pon A) 
The structure of compound AG-L-449.4 can be seen in Figure 35 and the purity of the isolated 
compound was ~85 %. The molecular formula was C27H44O5 and the isolated compound was a 
14-deoxy version of Pon A.  
 
 
Figure 35: Molecular structure of compound AG-L-449.4 and atomic numbering of the molecule. This molecule 
is a 14-deoxy version of Pon A (14-OH -> 14-H).  
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4.7 Bioactivity profile of BI-L-665.6 
The antibacterial activity of BI-L-665.6 was screened against the bacterial strains S.aureus, 
E.coli, E.faecalis, P.aeruginosa and S.agalactiae. No antibacterial activity was detected at the 
test concentrations.  The compound`s anticancer activity was screened against three different 
cancer cell lines (A2058, HT-29 and MCF-7) and no anticancer activity was detected against 
these cell lines at the test concentrations. In addition, the compound`s toxicity towards normal 
human cells (MRC-5) was screened at the same concentrations, and the compound was not 
toxic against the cell line at the test concentrations.  
4.8 Bioactivity profile of Pon A (AG-L-465.3) and dehydroxy-Pon A (AG-L-449.4) 
The antibacterial activity of Pon A was screened against the bacterial strains S.aureus, E.coli, 
E.faecalis, P.aeruginosa and S.agalactiae. No antibacterial activity was detected at the test 
concentrations. The anticancer activity of Pon A and dehydroxy-Pon A was screened against 
A2058 (with DMSO controls). The results can be seen in Figure 36. Both Pon A and dehydroxy-
Pon A had an effect on cell survival in some of the higher test concentrations. However, the 
DMSO controls show that the cells were affected by the amount of DMSO present in some of 
the test concentrations. Dehydroxy-Pon A had a slightly larger effect on the cell survival of 
A2058 than Pon-A in this screening, even at test concentration 150 µg/mL where the DMSO 
did not affect the cell survival.  
 
Figure 36: The effect of Pon A and dehydroxy-Pon A on the cell line A2058 were analysed in test concentrations 
ranging from 0.25 µg/mL to 250 µg/mL, with DMSO controls for each test concentration. The cell survival (%) 




The toxicity of Pon A and dehydroxy-Pon A towards MRC-5 was analysed (with DMSO 
controls). The results can be seen in Figure 37. Pon A and dehydroxy-Pon A  an effect on cell 
survival of the normal human cells at some of the higher test concentrations. However, the 
DMSO controls showed that the cells were also affected by the amount of DMSO present in 
the test concentrations. Dehydroxy-Pon A had a slightly larger effect on the cell survival of 
MRC-5 than Pon-A in this screening.  
 
Figure 37: The toxicity of Pon A and dehydroxy-Pon A towards MRC-5 were analysed in test concentrations 
ranging from 0.25 µg/mL to 250 µg/mL, with DMSO controls for each test concentration. The cell survival (%) 






Nature is a source of bioactive compounds with great chemical diversity, and the utilisation of 
NPs within the field of drug development has been a remarkable success. Historically, 
bioprospecting efforts have been focused on terrestrial species, while organisms living in the 
marine habitat largely were left unexplored. As the marine environment has been made more 
easily accessible (by improvements in scuba and submersible collection technologies), 
researchers have been able to focus on bioprospecting of marine species, including organisms 
harvested from the previously rather unexplored Arctic and Antarctic areas.  
The overall aim of this thesis was to identify and isolate bioactive secondary metabolites from 
Arctic, marine invertebrates. The invertebrates were collected and extracted by Marbank, and 
prefractionated and screened in a primary anticancer assay as part of the ongoing workflow at 
Marbio, before work with this thesis started. Through secondary anticancer screening, 
dereplication, isolation and NMR analysis, three compounds were isolated and their structures 
were elucidated. Two previously reported compounds, Pon A and dehydroxy-Pon A, were 
isolated from A.gelatinosum for the first time. One novel compound, named BI-L-665.6 in this 
thesis, was isolated from B.indet (species not determined, Celleporina surcularis cf). The 
bioactivities of the isolated compounds were explored. The strong anticancer effects observed 
in their originating fractions could not be explained by the purified compounds. 
5.1 Selection criteria for determining target compounds for isolation 
The target compound needs to be isolated in amounts that are sufficient for structure 
elucidation, bioactivity confirmation and preferably also for bioactivity profiling. In order to 
achieve this in the short time period available for this thesis, several criteria were used in order 
to select compounds that were possible to isolate in adequate amounts. The bioactivity focus in 
this thesis was anticancer and activity in a secondary anticancer screening was one of the criteria 
used for determining target compounds for isolation. In the initial anticancer screening, 19 
fractions were deemed active. While the primary anticancer screening tests the fractions at 50 
µg/mL, the secondary anticancer screening tests the fractions at 50, 25 and 10 µg/mL in order 
to eliminate false positives or to reveal if the activity is lost at lower concentrations. By 
conducting a secondary anticancer screening on the fractions included in this thesis, 10 out of 
19 fractions were eliminated. The reason behind the observed loss of activity is largely 
unknown, but might be due to sample content degradation, precipitation or other 
formation/decay of sample component aggregates (e.g. micelles) during storage (Di & Kerns, 
62 
 
2006; Eastwood et al., 2007). The results from the secondary anticancer screening allowed a 
focus on fractions with higher probability of containing compounds with activity against cancer 
cells and compounds that were stable enough to endure the treatment they would experience 
throughout the isolation process.   
The nine active fractions (from four different invertebrates) from the secondary anticancer 
screening were dereplicated using UPLC-HR-MS. An elemental composition was calculated 
for relevant compounds found in the fractions and database searches were conducted. In the 
dereplication results obtained in this thesis, three of the most common outcomes of 
dereplication analysis are nicely illustrated. The fractions ML-L-05, -L-06, L-07, W-05, W-06 
and W-07 contained phosphocholins (Figure 14 and Figure 15) and further work with these 
fractions was terminated. The fraction BI-W-05 contained a target compound that appeared to 
be novel and it was selected for isolation. The fraction PI-W-06 contained ianthelline that has 
reported anticancer activity (Hanssen, Andersen, et al., 2012; Hanssen et al., 2014), and work 
with this fraction was terminated. For fraction AG-L-05 it was difficult to determine the 
responsible bioactive compound(s) solely based on the results from UPLC-HR-MS analysis. A 
refractionation and tertiary anticancer screening was necessary to determine that AG-L-05 
contained several compounds that were believed to be novel, and these compounds were 
selected for isolation. As mentioned in the introduction, dereplication is conducted to lower the 
probability of isolation of already reported compounds (Blunt & Munro, 2014). By employing 
dereplication before isolation in this thesis, it was possible to eliminate further work with the 
fractions containing already reported bioactive compounds (phosphocholine and ianthelline).  
The elemental composition calculated in dereplication is a statistical calculation based on the 
mass spectrum of the target compounds. The researcher can influence this calculation based on 
the elements (and amount of the different elements present) that are included in the element list 
for calculation. E.g., including halogens if these are present in the mass spectrum or removing 
halogens if they are not present will narrow the number of possible candidates and make it more 
plausible that the calculation matches the actual elemental composition. There exist several 
challenges with using UPLC-HR-MS for dereplication, such as the difficulty in calculating an 
unambiguous elemental composition for compounds that only contain carbon, hydrogen, 
nitrogen and oxygen. This was experienced in this thesis with Pon A (AG-L-465.3) and the 
resulting database searches did not match with the already reported Pon A because the 
calculated elemental composition did not match with Pon A. The database searches gave four 
hits when the calculated elemental composition was used as search input. Based on the fact that 
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the calculated elemental composition only contained carbon, hydrogen and oxygen it was 
hypothesized that it would be difficult to calculate an unambiguous elemental composition. The 
compound was therefore nominated for isolation despite four hits in Dictionary of Marine 
Natural Products. Another challenge with using UPLC-HR-MS for dereplication is that the 
formation of adducts can affect the calculation of elemental composition (Kind 2010), and 
database searches. In this thesis, the formation of a sodium adduct complicated the calculation 
of the elemental composition for BI-L-665.6. This was not detected until after the compound 
was isolated. During dereplication, the three mentioned compounds were believed to be novel 
and were selected for isolation based on the criterias already mentioned.  
Two other inclusion criteria affected the evaluation of dereplication results. First, a compound 
was included because it was believed to be structurally similar to target compounds. The 
metabolic pathways producing secondary metabolites often result in the production of several 
similar secondary metabolites (Fischbach & Clardy, 2007). Isolation of closely related 
compounds is highly valuable because it can be used to make an assumption regarding the 
pharmacophore of bioactive compounds (structure-activity relationship analysis) (Guha, 2013; 
McKinney, Richard, Waller, Newman, & Gerberick, 2000). In the extract AG-L, a compound 
(named AG-L-449.4) was present and was believed to be a structural variant of the target 
compound AG-L-465.3 (see Figure 19 and Figure 21). Second, some compounds were included 
in the isolation due to their abundant presence in the crude extracts, e.g. AG-L-541.4 (see Figure 
32). This is normally not a major contributing factor in the process of selecting compounds for 
isolation at Marbio, but the limited time frame of this thesis necessitated strict inclusion criteria 
to ensure that compounds would be isolated in sufficient amounts for NMR analysis and 
bioactivity profiling. By considering factors like bioactivity, novel chemistry, possibility for 
structural variants and amount present in the extract, 11 compounds were isolated in the first 
crude separation of extracts BI-L and AG-L (Figure 26 and Figure 29).  
5.2 Establishment of isolation strategies to enable isolation of target compounds 
To establish an isolation strategy for the selected compounds, and to enable easy selection of 
columns for isolation steps after the first HPLC separation round, an initial scouting run was 
conducted. Here, the crude extract (pre-treated with a liquid-liquid partitioning step) was 
injected onto all five available prep HPLC columns.  Implementation of a scouting run offers 
three main advantages: 1) The researcher is able to pick the best column for the first HPLC 
separation round. 2) If the compound is not pure enough after the first round, the scouting run 
chromatograms can be used to evaluate which columns offer the best separation of the desired 
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compound, and the compounds that co-eluted with it in the first round. 3) A semi-purified 
sample will mainly contain your valuable target compound. Using the crude extract for the 
scouting runs instead of this sample avoids wasting valuable sample on HPLC separation 
optimisation.  
Different columns can be utilised to remove impurities and separate target compounds in 
several rounds of separation using prep HPLC-MS (Figure 38 and Figure 39). The columns 
have different packing material, but they may also differ in particle size and column dimensions, 
resulting in different separations of the sample components. In this thesis, five RP columns 
were used for HPLC separation (Figure 38). XTerra®, SunFire™ and Atlantis® have a C18 
hydrocarbon attached to their silica backbone, but they give rise to different separations because 
of differences in particle size and in silica-modifications. Fluoro-phenyl and Phenyl-hexyl share 
the same silica-backbone but differ in the groups coupled to this backbone, and therefore give 
rise to different separations (Waters, 2016). Scouting runs to determine which column gives the 
optimal separation of sample components should be conducted for each sample (Latif & Sarker, 
2012).   
 
Figure 38: Overview of the column material of the five different RP columns used in this thesis. The different 
coloured circles are representing the different silica backbone of the columns. Made with inspiration from 
reference (Waters, 2016).  
By combining several columns in the separation using prep HPLC-MS, we were able to purify 
three compounds in amounts that enabled elucidation of the structure: Pon A (AG-L-465.4), 
dehydroxy-Pon A (AG-L-449.4) and BI-L-665.6 (novel). Pon A and dehydroxy-Pon A were 
isolated using three rounds of separation with prep HPLC-MS, while BI-L-665.6 was isolated 
using two rounds of HPLC separation. Figure 39 exemplifies the effect of utilising different 




Figure 39: Chromatograms of the second and third separation round of AG-L-449.4, using prep HPLC-MS.  
Left) Chromatogram showing the second HPLC separation round of dehydroxy-Pon A (AG-L-449.4). In this 
round, the highlighted impurity (black arrow) was separated from the target compound dehydroxy-Pon A. Right) 
Chromatogram showing the third HPLC separation round of dehydroxy-Pon A. The semi-purified sample from 
the second separation, collected as seen in the chromatogram to the left, was injected onto a fluoro-phenyl column. 
The highlighted impurities (black arrows) all co-eluted with dehydroxy-Pon A in the second HPLC separation 
round, but were separated by employing a column with a different stationary phase in the third HPLC separation 
round. This shows the strength of employing columns with different stationary phases as part of the isolation.  
5.3 Characterisation of isolated compounds 
One of the major hurdles in marine NP drug discovery is the uncertainties surrounding supply 
of sufficient sample material and the difficulties regarding re-supply if more sample is needed 
on a later stage in the development process (David et al., 2015). Due to the low amount present 
of BI-L-665.6 in the sample after two HPLC separation rounds (Table 27), the compound was 
submitted for structure elucidation without any further purification. Elucidating the structure of 
BI-L-665.6 was complicated as the sample was not fully purified, and an unambiguous structure 
could not be decided. By using data simulations, a most probable structure was determined and 
this structure appears to be novel (even when allowing for structural dissimilarity in database 
searches). Due to the limited amounts available of BI-L-665.6, bioactivity profiling of this 
compound had to be done at low concentrations, and 10 µM was chosen as the highest assay 
concentration for this compound. The compound was not active at these concentrations, but it 
is still possible that it could be active at higher concentrations or in other bioassays than 
bioassays conducted in this thesis. Future work with this compound would involve isolating 
more of the compound (and purifying it further) from the aqueous extract of B.indet, a more 




Table 27: Collected wet weigh of the organism, weight of the isolated compounds and isolation yield of the 
isolated compounds BI-L-665.6, Pon A and dehydroxy-Pon A, isolated from B.indet and A.gelatinosum.   
Organism Wet weight Weight isolated compound Isolation yield 




Pon A: 1.25mg 0.06 % 
Dehydroxy-Pon A: 5.47mg 0.28 % 
 
Pon A and dehydroxy-Pon A were isolated in an amount that enabled a proper elucidation of 
the structure (Table 27). As mentioned, the calculated elemental composition for Pon A was 
not the same as the actual composition and the compound was falsely believed to be novel under 
dereplication. This compound has previously been isolated from the terrestrial plant P.nakaii in 
1966 (Nakanishi, Koreeda, Sasaki, Chang, & Hsu, 1966). Pon A is an insect hormone, involved 
in regulating metamorphosis, and it shows activity in moulting assay (moulting is the manner 
in which an animal routinely shed parts of its body). Variants of this compound (differing only 
in the position of one OH group, 14-OH or 9-OH) have also been reported (Nakanishi, 1992). 
Pon A is used as an inducer for gene-switch systems (suitable as an inducer of ecdysone-
inducible mammalian expression systems) and can be purchased from Sigma-Aldrich 
(Ponasterone A, P3490). To my knowledge, no other bioactivities have been reported for this 
steroid. In addition, Pon-A does not appear to have been isolated from A.gelatinosum 
previously. It could be discussed if the reason behind production of Pon A, with an effect against 
moulting, in this species could be predation pressure experienced in the marine environment.   
The antibacterial and anticancer activity of Pon A and dehydroxy-Pon A were analysed. The 
compounds displayed no antibacterial activity at the test concentrations employed (0.3125 µM 
to 10µM). Sample availability of Pon A and dehydroxy-Pon A was not a limiting factor in the 
biological characterisation conducted for this thesis, and test concentrations up to 250 µg/mL 
were used in the anticancer screening. Anticancer activity was detected for Pon A and 
dehydroxy-Pon A at some of the higher test concentrations (Figure 36). Generally, the DMSO 
controls also showed an effect on cell survival at these concentrations and it can be discussed 
if the anticancer activity was a result of the compounds, or the DMSO concentration. In this 
anticancer screening, it appears to be a result of both the compound`s anticancer activity and 
the DMSO present in the test sample. Pon A was detected in a fraction with anticancer activity 
in the secondary anticancer screening, but this initial activity was only confirmed at very high 
test concentrations in the bioactivity profiling of the compound. It is therefore likely that a 
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sample component other than Pon A, or in synergy with Pon A, was responsible for the 
anticancer activity in the secondary screening (Hay et al., 1998). It would be possible to test the 
anticancer activity in the fractions after each HPLC separation round (bioassay-guided 
fractionation) to counteract the possibility of isolating compounds that are not biological active 
when isolated (Guo, Wang, Zhu, & Xu, 2016). This is a time consuming process, sample is 
consumed during the bioactivity screening after each separation, and it was not prioritised for 
the work conducted in this thesis.  
In addition to information about the anticancer activity of the compounds, the results from the 
bioactivity profiling show that Pon A and dehydroxy-Pon A were toxic against normal human 
cells (see Figure 37). This is valuable information if these compounds show bioactivities in 
“non-cancer related” bioassays in the future, and therefore become drug candidates for other 
areas than cancer. New ways of delivering drugs (drug-antibody conjugates) may enable these 
compounds to be used as drugs despite this toxic effect against normal human cells (Ducry & 
Stump, 2010).  
The results from this thesis indicated that dehydroxy-Pon A had a greater activity towards the 
cancer cell line,as well as the normal human cells, compared to Pon A. It is possible that the 
OH group at carbon 14 affects the activity displayed by these compounds. Earlier studies have 
showed that removal of the 14-OH increased the binding affinity to receptors five- to eightfold 
(Cherbas, Trainor, Stonard, & Nakanishi, 1982). Investigating the structure-activity 
relationship for these compounds would be a possible next step for characterising these 
compounds further. In addition, the compounds could be screened in other bioassays to fully 





6 Conclusions  
By following strict criteria to initiate isolation of compounds in amounts that enabled structure 
elucidation and biological characterisation, three compounds were isolated and characterised in 
this thesis. One novel compound (BI-L-665.6) was isolated from B.indet, and a previously 
reported compound (Pon A), as well as a structural variant of this compound (dehydroxy-Pon 
A), were isolated from A.gelatinosum. BI-L-665.6 did not display antibacterial or anticancer 
activity at the concentrations screened in the bioassays. Pon A and dehydroxy-Pon A did not 
display antibacterial activity, but the compounds displayed minor anticancer activity at the test 
concentrations employed in the bioassay.  
The results in this thesis demonstrate:  
 The importance of dereplication to eliminate samples which should not be prioritised in 
a bioprospecting pipeline 
 The importance of establishing isolation strategies to enable isolation of target 
compounds in amounts sufficient for structure elucidation and biological 
characterisation 
 That structural variants of target compounds can be isolated together with the target 
compound, if a thorough dereplication is conducted prior to isolation  
 That bioprospecting of collected marine invertebrates enables discovery of secondary 
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Instrument parameters used for UHPLC-HR-MS analysis of active samples from the secondary 
anticancer screening can be seen in Table 28.  
Table 28: Instrument parameters for UHPLC-HR-MS.  
Polarity Positive 
Low mass 150 m/z 
High mass 1500 m/z 
Scan time 0.2 s 
Source type ESI 
Source temperature 120 ˚C 
Desolvation temperature   300 ˚C 
Desolvation gas flow 600 L/hour 
Cone gas flow 5 L/hour 
Cone voltage 110 V 
Capillary voltage 2.6 kV 
 
A2: Prep-HPLC-MS 
Instrument parameters used for prep HPLC-MS refractionation of sample AG-L-05 and 
isolation of sample AG-L and BI-L can be seen in Table 29.  
Table 29: Instrument parameters for prep HPLC-MS.  
Polarity Positive 
Low mass 250 m/z 
High mass  1100 m/z 
Scan time 1 s 
Source type ESI 
Source temperature 120 ˚C 
Desolvation temperature 300 ˚C 
Desolvation gas flow 650 L/hour 
Cone gas flow  5 L/hour 
Cone voltage 42 V 
Capillary voltage 3 kV 
 
A3: UPLC-QToF-MS 
Instrument parameters used in UPLC-QToF-MS analysis of isolated compounds can be seen in 
Table 30.  
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Table 30: Instrument parameters for UPLC-QToF-MS. 
Polarity Positive 
Low mass 50 m/z 
High mass 1500 m/z 
Scan time 0.20 s 
Source type ESI 
Source temperature 120˚C 
Desolvation temperature 500˚C 
Desolvation gas flow 800 L/h 
Cone gas flow 50 L/h 
Cone voltage 30 V 
Capillary voltage 0.8 kV 
 
A4: Isolation using prep-HPLC-Ms, sample BI-L 
Five different columns were evaluated for their ability to separate the compound of interest 
from each other as well as from impurities in extract BI-L (Figure 40).  
 
Figure 40: BPI chromatogram of isolation of the organic extract BI-L on five different columns with elution 
gradient 1. A: Atlantis column, B: XTerra column, C: Phenyl-hexyl column, D: Fluoro-phenyl, E: SunFire. Phenyl-
hexyl was used for the first round of HPLC separation.  
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A5: Isolation using prep-HPLC-MS, sample AG-L 
Five different columns were evaluated for their ability to separate the compound of interest 
from each other as well as from impurities in extract AG-L (Figure 41).  
 
Figure 41: BPI chromatograms of isolation of the organic extract AG-L on five different columns with elution 
gradient 1. A: Atlantis column, B: XTerra column, C: Phenyl-hexyl column, D: Fluoro-phenyl, E: SunFire. Pheny-
hexyl was used for the first round of HPLC separation.  
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A6: Poster presented at BIOPROSP 2017 
 
 
